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ABSTRACT 
 
The chemical characterization of nanomaterials in the realm of drug delivery and 
surface modification is on the current frontiers of analytical chemistry. A drug delivery 
vehicle must be able to carry therapeutic cargo and be able to reach the intended target 
or compartment. This dissertation will focus on the analytical characterization of 
zirconium phosphate (ZrP) in both alpha and theta phases as a drug delivery matrix 
utilizing multiple unique and novel analytical techniques.  
In the first area we present for the first time, a methodology for the 
characterization of individual drug loaded 150 nm ZrP nanoparticles (NPs) by obtaining 
molecular information from single massive cluster impacts. The clusters used in this 
secondary ion mass spectrometry (SIMS) technique are Au400
4+ and C60
+/2+. The ionized 
ejecta from each impact are recorded individually which identifies ions emitted from a 
surface volume of ~10 nm in diameter and 5-10 nm in depth. The mode of analyzing 
ejecta individually from each single cluster impact gives insight into chemical 
homogeneity within nanodomains.  
The in vitro biological release profile was investigated in simulated biological 
environment for the drug-ZrP nanocomposites. The release profiles reveal a direct 
dependency with the pH of the medium for the release of the complexes indicating 
targeting opportunities. Additionally the NP matrix breaks down in the artificial 
lysosomal fluid medium at pH – 4.5 indicating good bio-clearance possibilities, a major 
issue that plagues several alternative drug delivery carriers. This project is expected to 
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give rise to a facile drug delivery matrix that is highly biocompatible and leads to greater 
targeted gentoxicity for cancerous cells.  
The second area of research presented in this dissertation investigates the surface 
modification of 150 nm α-ZrP NPs utilizing a host of different organo modifiers. α-ZrP 
was surface modified by reacting surface P-OH groups with 3-(triethoxysilyl)propyl 
isocyanate(TEPI), dichloromethyl(phenyl)silane(DCMPS) and lauryl 
methacrylate(LMA). SIMS in the event-by-event bombardment detection mode was 
utilized to calculate the degree of surface coverage for a brand new platform in 
conjunction with TGA, FTIR and XRPD to detail the surface confinement of the 
molecular assemblies. New discoveries continue to be made by creative scientists’ 
everyday pushing what we know about inorganic layered materials and the analytical 
chemistry that drives this field.   
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CHAPTER I 
INTRODUCTION 
 
The word ‘nano’ is derived from the Greek word ‘nanos’ meaning ‘dwarf’. The 
prophetic talk entitled, “There’s plenty of room at the bottom”, by physicist Richard 
Feynman in 1959 marked the advent of nanotechnology. Over five decades later, 
nanotechnology has come a long way since its inception. One of those influential areas 
of nanotechnology is in the research and development of inorganic nanomaterials.1 The 
versatility in applicability makes these materials highly attractive for a wide gamut of 
utilities.  
Inorganic layered materials are one such area of innovative research. Their 
unique properties have given rise to a wide range of applications that has shown promise 
as high performance materials. From surface tethered molecular components that can 
serve a multitude of scopes, including coupling biomaterials,2 to electron transfer 
reactions,3-5 sensors and biochips,6, 7 drug delivery,8-11 photovoltaic,12, 13 fuel cell,14 and 
molecular electronics,2, 12, 15  to controlling reactions at surfaces,5 and tailoring surface 
properties. In addition, inorganic layered materials allow for greater exploitation 
potential through a wide range of intercalation chemistries. With modifications in 
synthetic parameters such as temperature, pressure, reaction time, concentration of 
reactants and the use of complexing agents it is possible to control particle size, 
morphology, crystallinity and aspect ratio. 
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This dissertation is centered on the synthetic modifications of a model system, 
zirconium phosphate (ZrP) of composition Zr(O2POH)2.H2O, an inorganic layered 
nanomaterial and their subsequent use in developing new and unique analytical 
methodologies for nanodomain characterization. The ZrP material modifications 
proposed in the first half of this thesis are selectively sequestered onto the surface to 
establish a fundamental understanding of the surface chemistries. The lack of selectivity 
and sufficient delivery of the current anticancer agents in use is a major cause of severe side 
effects and treatment failures today. The second half of this thesis focuses on studies 
exploiting the intercalation chemistry of ZrP for the targeted delivery of anticancer drug 
therapeutics to cancerous cells and the controlled release of the drugs in-vitro. This 
assertion is illustrated by placing varied levels of anticancer drugs doxorubicin and 
cisplatin within the layers and using a host of analytical techniques to interrogate the 
resultant materials.   
When it comes to the characterization of morphologies in the nanometric scale 
there is a general consensus that more needs to be done to improve their 
characterization.16,17 During the course of this dissertation another focus will be using 
the novel analytical technique of secondary ion mass spectrometry (SIMS), a highly 
surface sensitive technique which provides a wide range of chemical and molecular 
information.  Two main topics are investigated and discussed using this technique 1) 
characterizing the extent of surface modification onto the ZrP platforms with a variety of 
functionalities 2) investigating and discussing the application of cluster time of flight 
secondary ion mass spectrometry (ToF-SIMS) in the analysis of homogeneity 
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characterization for drug distribution within the ZrP matrix. The goals of both these 
studies were twofold: a) to devise new and unique methodology for inorganic layered 
material sample preparation for analysis in vacuum environments independent of 
modification, b) to interrogate and establish a protocol for quantifying the extent of 
surface coverage for the surface modified samples and the degree of material 
homogeneity for the intercalated samples. The analysis in both studies was performed in 
the negative ion mode using a custom built ToF-SIMS instrument which I will introduce 
in detail in the following chapter. Prior to the presentation of each individual study and 
sample preparation methodology it is useful to recall the scope of relevant advances in 
ZrP material design.     
      
Zirconium Phosphates  
Stemming from the need to exert higher control on surface and intercalation 
chemistries, zirconium phosphate (ZrP), Zr (HPO4)2. nH2O a synthetic layered 
compound with a very well ordered structure was chosen to be the model material during 
the course of discussions in this thesis. It was first discovered in 1964 by Clearfield and 
Stynes via refluxing amorphous ZrP with phosphoric acid.18 This layered material, ZrP 
is not unlike montmorillonite clays. With a high ion exchange capacity of 6.64 meq/g the 
material consists of Zr, P and O atoms. The structure consists of an octahedral sheet of 
Zr atoms linked by tetrahedrally oriented phosphate groups. Hydroxy groups orient into 
the interlayer planes. These –OH groups lend ZrP its, acidic character allowing for ease 
of ion exchange by a variety of cationic species. They have high thermal and chemical  
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stability, solid state ion conductivity, resistance to ionizing radiation, and the capacity to 
incorporate different types of molecules with different sizes between their layers.8-11, 19-21 
While there are several phases of ZrP the phases that my dissertation will concentrate on 
include the alpha phase (Zr (HPO4)2·H2O) which has an interlayer space of about 7.6 
Å and the hydrated theta phase (Zr (HPO4)2·6H2O) with an interlayer spacing of about 
10.4Å.22  
Figure (I-1a&b) shows the alpha phases of zirconium phosphate in its idealized 
structures. The crystal structure for the alpha phase was first elucidated by Clearfield and 
coworkers in 1968 utilizing the single crystal-methodology.23, 24 In the alpha phase the 
material layer thickness is about 6.6Å with the remaining 1Å being occupied by the 
interstitial water molecule. 23, 24 The adjacent orthophosphate groups on the ab plane are 
5.3Å apart allowing for two phosphate groups on the mentioned plane. 23 The associated 
area for each phosphate group is thus, 24Å2. The interstitial water molecule resides in 
the zeolite-like cavity forming a hydrogen bond with the P-O-H oxygen groups located 
perpendicularly (Figure I-1c). Van der Waals forces hold the layers together giving it its 
characteristic lamellar structure. 23  
The theta phase of zirconium phosphate is the hydrated phase with six moles of 
water in contrast to the one mole in the alpha phase. The crystal structure for this 
material still remains unresolved. First reported in 1969 by Alberti and Torracca25 and 
separately by Clearfield et al.26 The wide usage of the material didn’t take off until 1982 
when Kijima22 first investigated the effects of temperature and Zr concentrations in 
solution to obtain pure θ-zirconium phosphate (θ-ZrP) at different levels of crystallinity. 
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Dilute solutions (0.05M) of ZrOC12.8H2O in 6M H3P04 heated at 60-94°C for 48 h or 
longer yields only θ-ZrP, which reverts to α-ZrP on drying (Figure I-2).27 Fujita and 
Hasegawa in 1985 were the first research group to report the pronounced ability of θ-ZrP 
to sequester large cations when they ion exchanged hexaaminecobalt (III) into the θ-ZrP. 
Since then, this unique increased layer spacing has allowed the theta phase the ability to 
entrap several relatively large cations compared to its alpha counter-part.8-10, 20, 28, 29 In 
addition, the chemical structure and hexagonal nano-platelet like shape of each ZrP layer 
remains relatively unchanged from the original alpha phase. 
In the quest for new and improved synthetic techniques to allow for greater 
control in particle size, morphology and crystallinity significant strides have been made 
since the inception of the ZrP materials. In 2007, Sun and coworkers produced a host of 
different α-ZrPs with a wide variation in aspect ratios by controlling the concentration of 
reactants, temperature, pressure and the use of complexing agents.30 The resultant 
materials ranged from nano to micro dimension sizes and varied crystallinity. Figure I-3 
shows SEM images of six of those materials synthesized displaying an assortment of 
particle sizes. More recently, Pica and coworkers report a new synthetic route for ZrP 
synthesis using aliphatic alcohols to produce even smaller particle sizes than previously 
known.31 The planar sizes varied from 90-200 nm and thickness from 20 to 85nm 
depending on the solvent.31 Figure I-3 shows the TEM images for these new compounds.  
In this next section I will discuss some of the different mechanisms that are generally 
employed in the intercalation and subsequent encapsulation of a variety of species within 
the ZrP layers will be discussed.     
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7.6Å 10.4Å
Upon Drying 
Upon Hydrating 
Figure I-2: Top: Idealized structure of α-ZrP and θ-ZrP. Bottom: XRPD 
pattern of θ-ZrP(red) and α-ZrP(blue). Modified from references (9 and 
25)    
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(a) ZrP (6M) (d) ZrP (9M)
(e)ZrP (9M-200 C-24h)(b) ZrP (12M-200 C-24h)
(c) ZrP (HF2) (f) ZrP (HF4)
(g) ZrP (2-ol)
(h) ZrP (3-ol)
(i) ZrP (4-ol)
Figure I-3. SEM (a-f) and TEM (g-i) images of α-zirconium phosphate 
nanoplatelets synthesized under different conditions producing a wide range of 
particles varying in size and crystallinity. (Adapted from references 29 & 30)  
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Zirconium Phosphate Intercalation Chemistry 
 According to the Merriam Webster dictionary, intercalation is simply the act of 
inserting between or among existing elements or layers. Layered materials by virtue of 
their inherent physiology possess the ability to entrap a variety of species. The process 
by which a guest molecule or ion maybe sequestered within a host matrix is 
intercalation. The structure of the guest-host or intercalation compound is only slightly 
perturbed from its original host structure and in most cases, this reaction is reversible.32 
The relationships responsible for the sequestration of the guest molecule are varied and 
the levels of loading are determined by a variety of interactions. In the case of zirconium 
phosphate chemistry, intercalation occurs through three predominant mechanisms: ion-
exchange, acid-base reaction or through charge-transfer (Figure I-4).33 These reactions 
are known to be topotactic, i.e. they displace pre-existing layers to make room for new 
species.34 Therefore, the first diffraction peak at the lowest 2θ angle in the X-ray powder 
diffractograms corresponds to the interlayer distance.35 By monitoring newly formed 
phases using the Rietveld refinement method and XRPD pattern it is possible to gauge 
intercalations. This was confirmed by Clearfield and coworkers via the elucidation of the 
crystal structure of the two phases of pre and post intercalated α-ZrP with guest 
molecules.36, 37 Each of these mechanisms may work independently or in combination to 
allow for guest molecule encapsulation. 
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Ion Exchange  
In the case of the ion exchange reactions, the protons present in the inner lattice 
attributed to the phosphate groups are easily exchanged to incorporate the charged guest 
species. The direct ion exchange of small ions (diameter < 2.61 Å) such as Na+ is a very 
well established ZrP intercalation reaction, involving the direct suspension of the 
material in a solution containing sodium chloride and sodium hydroxide.38 In addition, 
several cations such as Li+, Ag+, Tl+, Cu+, Ca2+ among many others can easily be 
sequestered in the interlayer phosphate.39 These newly formed intercalated materials 
show the appearance of a newly formed phase in each case which is directly related to 
the size of each individual species and the electrostatic forces between the guest ion ad 
interlamellar regions.39 While direct ion-exchange works relatively well for the smaller 
cations, in the case of the larger cations such as Rb+, Cs+, Ba2+ and NH4
+ diffusion into 
α-ZrP is poor.33 Research indicates cations larger than 2.63 Å in diameter don’t tend to 
directly ion exchange into α-ZrP.38   In 2002, Colón and coworkers reported the direct 
ion exchange of luminescent metal complexes such as tris(2,2′-bipyridine)ruthenium(II), 
Ru(bpy)3
2+ using θ-ZrP.40 The high ion exchange capacity of ZrP makes it an 
exceptional candidate for a variety of material encapsulation type reactions. 
 
Acid-Base  
 The acidity of the inner lattice of ZrP allows for easy acid-base intercalations. An 
acid−base reaction occurs, when a proton is transferred from the −POH group to the 
basic species by deprotonation. The intercalation is driven by the presence of this 
11 
 
medium strong P-OH Bronsted acid group in the inner layer. The incoming guest species 
would act as a base reacting with the inner lattice phosphate groups permeating the inner 
galleries resulting in a positively charged guest species being neutralized by the 
deprotonated phosphate groups. Compounds with proton accepting functionalities such 
as amines are a very good example for the acid-base driven intercalation reactions.41 
Several ammonium salts and alkylamines have been successfully incorporated into the 
ZrP layers utilizing this mechanism.42 Clearfield and coworkers estimated the potential 
molecular arrangement of n-butylamine intercalated into ZrP by accounting for the guest 
molecule elemental composition and potential change in interlayer distance attributed to 
the guest molecule’s dimensions.43 The appearance of a new phase at 18.6 Å helped 
identify the n-butylamine addition within the ZrP layers via the acid-base reaction 
mechanism.43 Additionally by changing the concentration of the guest molecule, n-
butylamine additional new phases were identified.43     
   
Redox 
 Oxidation-reduction reactions, although a bit uncommon, have also been known 
to drive intercalation reactions for guest molecules. The oxidizing effect of the acidic 
inter layers may cause the oxidation of the intercalating guest species in the process 
driving the redox reaction. In 1980 Johnson reports the intercalation of organometallic 
guest species, such as cobaltocene.44 The cobaltocene is intercalated into γ-ZrP as 
cobaltocenium cation.44 θ-ZrP has been employed to intercalate ferrocene to produce a 
ferrocenium ion loaded material.45 Any of these individual mechanisms or any 
12 
 
combination of them can be used to expand the possibilities of encapsulated species for a 
large variety of applications.  
 The intercalation of large species into α-ZrP isn’t very favorable due to the 
intercalation energy barrier posed by larger guest species. In order to overcome 
challenges posed and allow for facile access of the inner layers the γ-ZrP and θ-ZrP with 
their enhanced layer spacings are used to incorporate larger molecules. Additionally the 
use of preswelling agents such as sodium ion exchanged ZrP also allows to expand inner 
layers can also be used to overcome the intercalation energy barrier.39 Therefore it is 
possible to exploit additional chemistries to open up additional possibilities in the realm 
of intercalation.   
 
Drug Delivery Rationale  
 In our daily lives, the word ‘deliver’ has several meanings. Arguably, it is most 
commonly used in the sense ‘to send to an intended target or destination’. Nanomedicine 
is a fast evolving field involving the use of nanostructures for medical applications. The 
need to maximize therapeutic activity while minimizing negative side effects is driving 
current drug delivery attempts. With nanomedicine for the first time we have the 
possibility of designing specialized systems to meet specific requirements of targeted 
cargo delivery, higher drug bioavailability and most importantly reduced genotoxicity. 
In this fast evolving field inorganic layered nanomaterials (ILN) have received a great  
deal of attention of late.  
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In 1997 Danjo and coworkers reported the intercalation of anticancer agent cytarabine 
into γ-titanium phosphate.46 Layered double hydroxides another class of ILN consisting 
of cationic brucite-like layers with anion exchangeable inner lamella that have been used 
to encapsulate a variety of drugs such as fenbufen,47 naproxen,48 salicylate48 along with a 
large host of other non-steroidal anti-inflammatory drugs (NSAIDs) pain relievers.49 In 
addition, Choy and coworkers have reported biomolecular–inorganic hybrids using 
cationic LDHs to encapsulate anionic biomolecules (such as DNA fragments, ATP, or an 
antisense oligonucleotide).50 Thus, the central idea behind the use of laminar 
nanostructures is to allow for a variety of drugs and biomolecules to be easily 
encapsulated within the interlayer galleries while being protected. The size tunability of 
these materials makes them particularly attractive vehicles since the ideal size required 
for incorporation of nanodevices is predominantly in the 100-300nm range. This allow 
for delivery in tissues that have a fenestrated vasculature and a reduced lymphatic 
drainage as is the case with typical neoplastic tissues.51 Additionally the flexibility in 
surface modifying these materials with a host of different surfactants also allows for 
greater targeting specificity. 
 The rationale behind the design of nanocarriers for cancer therapy was eloquently 
described by Peer and coworkers. They outline, nanocarriers offer several advantages 
over free drugs: (1) they protect the drug from premature degradation; (2) prevent 
extraneous interactions; (3) increase effective dosage through enhanced absorption by 
target tissues through effective distribution (4) control pharmacokinetic and drug tissue 
distribution profile; (5) improve intracellular penetration.52 Some of the essential 
15 
 
characteristics that make up an effective nanocarrier include: (1) being made from 
biocompatible materials, well characterized, and easily functionalized; (2) exhibiting 
high uptake efficiency at target cells over normal (healthy) tissue; (3) be soluble or 
colloidal under aqueous conditions for increased effectiveness; (4) have an enhanced 
permeability and retention along with an extended circulating half-life, a low rate of 
aggregation and a long shelf life.52, 53     
 
Zirconium Phosphate in Drug Delivery  
ZrP has been used in biological applications, ranging from its use as a dialyzer54 
to its applications in drug delivery.8-11 In humans, Zr is not considered an industrial 
health hazard.55 Zr based compounds have been used in dental implants and other 
restorative practices,56-59 total knee60 and hip replacements,61, 62 and ossicular chain 
reconstructions.63 Zr-containing sorbents such as ZrP have been used extensively and for 
several years successfully and without complications in hemofiltration,64-66 
hemodialysis,67 peritoneal dialysis,68 and in the design and construction of artificial 
kidneys.69-71 Additionally, other Zr based compounds have been used extensively in 
deodorants and antiperspirants for decades. Experimental and clinical studies support the 
general consensus that Zr compounds are biocompatible and exhibit low toxicity.  
Reports of Zr toxicity in medical literature are few and far between, despite the 
increasing use of Zr based compounds in biological applications.72   All the evidence 
from the medical and chemical community seems to suggest that ZrP materials have all 
the ideal characteristics to be successfully used as a carrier in a biological system. The 
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high ion-exchange capacity and known activity towards bioactive materials make it an 
attractive target for biological applications, especially in the realm of drug delivery. 
Among the wide variety of species that could possibly be intercalated into the variety of 
ZrP phases are drugs, dyes, MRI contrasts agents, proteins, enzymes, genes, etc. Reports 
of Zr toxicity in medical literature are few and far between, despite the increasing use of 
Zr based compounds in biological applications.72   All the evidence from the medical and 
chemical community seems to suggest that ZrP materials have all the ideal 
characteristics to be successfully used as a carrier in a biological system. The high ion-
exchange capacity and known activity towards bioactive materials make it an attractive 
target for biological applications, especially in the realm of drug delivery. Among the 
wide variety of species that could possibly be intercalated into the variety of ZrP phases 
are drugs, dyes, MRI contrasts agents, proteins, enzymes, genes, etc. 
 
Improving Drug Efficacy through Delivery 
 Improving drug efficacy in hard to fight malignancies can help turn the tide in 
treatment effects. While new drug discovery is essential, improving the delivery efficacy 
of existing therapies can only help the bottom line. By changing the loading levels 
(LDL) of the bioactive species within the layers of inorganic layered materials, such as 
ZrP it is possible to control their concentration allowing for a greater control in potential 
pharmacological release. Additionally by synthesizing the ZrP, based on custom size 
needs the LDLs can be further influenced.  
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Biocompatibility 
Targeting Uptake
Drug 
Delivery
Outcome
Figure I-5: Cartoon representation of the three most basic and important 
characteristics involved in the successful design of a drug delivery system that 
influences potential outcomes.  
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Characteristically the release profile for most inorganic layered materials 
depends on or may be negotiated via a chemical switch, concentration gradient, pH 
change and/or biological stimuli.73 By employing surface functionalization and grafting  
biologically relevant targeting moieties onto the surface of the ZrP platelets it is possible 
to further enable effective targeting and increased biocompatibility and cellular 
retention, all crucial factors in successful drug delivery agents (Figure I-5). The unique 
platelet-like shape, presented by the ZrP particles, provides additional surface area of 
interaction compared to their spherical counterparts. In comparison with polymer drug 
delivery agents, ILN like ZrP allow for much more effective characterization by 
exploiting their well-studied crystal structure. By employing standard analytical 
techniques it is possible to gauge the bioactive species LDL with relative ease. 
Moreover, ZrP is pH sensitive making it an ideal candidate for drug delivery via oral 
uptake and tumor site release, since the material is relatively robust. Ferrari and 
coworkers, discuss in length the downfalls of spherical drug delivery agents. They allege 
that spherical particles exhibit the poorest margination properties, penetration through 
vascular fenestration (a crucial factor in uptake through tumor sites) and adherence to the 
endothelial walls - hampering effective cellular uptake. 74-77  
 
Challenges in Drug Delivery  
 With a clearer idea of what makes a superlative drug delivery vehicle it becomes 
even more crucial to know what factors directly hamper its transport. Figure I-6 
highlights several of the obstacles that a nanoparticle drug delivery system needs to  
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overcome in order to reach its intended target. These biological barriers largely prevent 
any injected nanocarriers from actively interacting with their destination. These barriers 
include but aren’t limited to: (a) the reticulo-endothelial system, (b)endothelial/epithelial 
membranes, (c) complex networks of blood vessels (d) abnormal flow of blood and (e) 
interstitial pressure gradients.77     
In order to overcome several of these challenges overtime it has become crucial 
to invent new and innovative design ideas to exploit pre-existing tumor physiology and 
motivate innovative drug delivery design. The pre –existing vascularization of tumor 
cells allows for greater nanoparticle penetration (Figure I-7). Nanoparticles designed to 
be large enough to access these cancerous tissues but small enough to avoid 
incorporation into healthy tissues exploit one such aspect of tumor physiology. 
Additionally, once a nanoparticle has successfully reached a tumor site, another 
interesting stimulus that a tumor site affords is a lower more acidic pH 
microenvironment compared to normal tissues. This is attributed to major mechanisms 
including the production of lactic acid and hydrolysis of ATP in hypoxic regions.78 It has 
also been hypothesized that the pH of solid tumors is acidic due to increased 
fermentative metabolism and poor perfusion.79  While the absorption of calcium, 
magnesium, sodium and oxygen is hampered, making a tumor microenvironment 
anaerobic; glucose transport remains unaffected. This kind of activity leads to 
fermentation, causing a lactic acid buildup, leading to a low pH environment. Inefficient 
energy production and usage propels tumor tissues into the starvation mode causing 
incoherent cellular assembly. This allows tumor cells to uptake larger particles than 
21 
 
healthy normal cells under usual conditions due to the enhanced permeability of the 
cancerous cells. Additionally, the epithelial walls around cancerous tissue sites are 
highly capillarized and vascularized allowing for much greater permeability. Hyper‐
permeable tumor vasculature allows preferential extravasation of the circulating drug 
carriers due to enhanced permeability and retention (EPR) effect.80 If the drug delivery 
vehicle cannot deliver its cargo to the interior of the cell where it can be active, the 
benefits of using a drug delivery vehicle are greatly diminished. Developing a drug 
delivery vehicle that is simultaneously able to maintain a long circulation half-life while 
also being able to deliver its cargo to the interior of the cell remains a key challenge in 
systemic delivery.  
Another very important feature of an effective drug delivery agent is the release 
profile exhibited by the subjective delivery agent in different biological media. Different 
drugs have different concentration dependent therapeutic windows. When the drug 
loading concentration falls below its critical level of effectiveness, the drug stops being 
efficient. Conversely, if too much of the drug is loaded into the NP delivery system then 
it will start exhibiting all the treatment effects of the pristine drug, as is the case in many 
chemotherapeutics.  
Designing a drug delivery system that can release its cargo in a controlled release 
fashion over a period of time can serve as an internal safe house. This helps maintain 
active drug concentration in the blood stream during the required therapeutic window of 
effectiveness preventing unwanted side effects. The drug release profile remains one of 
the key parameters tuned by researchers in order to maximize the benefits of using a 
22 
 
drug delivery vehicle. Layered materials such as ZrP allow for step-wise drug release 
and that is one of the characteristics of ZrP that will be uncovered and discussed in the 
course of this dissertation. This dissertation will also discuss several of these outlined 
key challenges when pursuing ZrP in drug delivery strategies.  
 
Characterization of Nanoparticles 
 In addition to the challenges posed in designing a drug delivery carrier additional 
challenges arise on the analytical front. Despite the use of nanoparticles in a wide range 
of applications, only a limited number of analytical techniques exist for their 
characterization. In order to design effective carriers for delivery and/or for surface 
functionalization a real need exists for effective and efficient characterization to verify 
material quality from one synthetic batch to the next. As the field of nanotechnology 
grows, it becomes increasingly important not only to explicitly identify the chemical 
composition of NPs themselves, but also of the functionalization or surface modification 
of the NPs.81 A comparison of the spatial resolutions and sensitivities for several 
analytical techniques currently used in nanoparticle characterization is shown in Figure 
I-8and a comparison of their analytical depths is shown in Figure I-9.82  
Techniques such as transmission emission microscopy (TEM) and scanning electron 
microscopy (SEM) are sensitive to surface morphology of NPs. However, due to the 
high fluence of electrons in both techniques; their applicability in imaging biomolecules 
is relatively limited.83 This leads to the need for dyes and fluorescent biomarkers in order 
to tag and follow relevant molecules of interest. These often involve complicated sample  
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preparation and pretreatment. Additionally complications also often rise from overlap of 
different labels reducing specificity and accuracy of measurement. In order to 
circumvent challenges posed by enhanced electron fluence, low acceleration beam 
energies   (< 2 Kev) are often used. This however diminishes image resolution and 
quality. SEM resolution limits its use for the characterization of nanoparticles with sizes 
smaller than 5 nm for a cellular environment. 
Optical imaging (OI) can be used to image NPs > 20 nm in the phase contrast 
mode or differential interference contrast mode; fluorescence microscopy can detect 
particles at the singular entity level;84 Several of the techniques listed in Figure I-8 offer 
isotopic information but no molecular information. Other techniques provide chemical 
information like in the case of derivatized AFM tips, infrared (IR) and Raman 
spectroscopy and are nondestructive. XPS has been utilized to characterize surface 
coverage of DNA/alkylthiol monolayers by the Castner group.85, 86 It is known to 
provide information of the outermost ~10 nm of surface modified material. The use of an 
x-ray probe limits XPS imaging to a submicron-scale lateral resolution due to challenges 
arising from focusing. 
Mass spectrometry is well suited for the analysis of NPs to yield chemically 
relevant information. The use of mass spectrometry in nanotechnology studies have 
focused on mass determinations of various sizes and types of NPs.87-89 In the realm of 
drug delivery the fabrication of controlled-release systems can be technically difficult 
compared with conventional dosage forms, evaluation and analysis of the final product is 
vital. Dissolution studies have been used in the past to observe drug release; however  
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any unwanted effects cannot be readily attributed to specific defects within the carrier 
structure and/or composition. To overcome this, mass spectrometry based techniques are 
used to probe cross sections of the drug-matrix composite. Mass spectrometry, 
specifically time of flight secondary ion mass spectrometry (ToF-SIMS) has been used 
extensively to characterize polymeric drug delivery systems.90-97 TOF-SIMS has also 
been used extensively in the study of inorganic materials.98-101 However, using the 
technique for the characterization of inorganic layered nanomaterials in drug delivery 
remains a relatively scarce area of analytical research as far as we are aware. In the 
subsequent dissertation chapters the efficacy of the technique in drug delivery analysis 
of ILNs will become apparent.          
 
Secondary Ion Mass Spectrometry (SIMS) 
Secondary Ion Mass Spectrometry (SIMS) is a mass spectral technique that is 
capable of obtaining molecular chemical information from NPs. It is a surface analysis 
technique where primary ions which can be atomic or polyatomic are used to sputter 
positively and negatively charged secondary ions. It involves the use of energetic 
projectiles (primary ions) to bombard analyte surfaces, which induce the sputtering of 
secondary species (electrons, photons, atomic and polyatomic ions, and neutrals). A 
general schematic for the SIMS experiment is presented in Figure I-10.   The technique 
provides molecular, chemical and isotopic information. It can also be used in depth 
profiling analytes. In its early years SIMS was and to a large extent still is used heavily 
by the semiconductor industry.100 Traditionally, atomic projectiles such as Ar+, Ga+,  
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C60
+, or alkali metal are used as primary projectiles.  SIMS does not require a matrix, 
fluorescent, or isotopic labeling, which eliminates sample preparation and allows direct 
characterization of native sample species (organic &inorganic) to be performed.  With 
the discovery of cluster projectiles the realm of SIMS analysis has extended into 
applications in molecular and biological imaging. In the following sections, the 
principles of secondary ion mass spectrometry as it relates to this thesis will be 
presented.  
 
Dynamic vs. Static Regime  
     Secondary ion mass spectrometry can be divided into two broad strata based on 
the dosage of primary ions delivery to the sample target of interest.  At high doses ~10 12 
ions/cm2 the mode of operation is considered to be “dynamic” SIMS. In this mode both 
elemental as well as isotopic information can be extracted from the samples of interest. 
The detection sensitivity of the technique is in the ppm - ppb range for all elements. In 
dynamic SIMS a primary ion beam is used to raster material from a small target to 
obtain layer-by-layer information in a well-defined sample area. This technique is 
generally considered destructive since secondary ions produces undergo extensive 
fragmentation, which limits most studies to elemental and isotopic distribution analyses. 
That being said, it is possible to obtain three-dimensional chemical information (depth 
profiles) of the targets of interest.102  
 When the primary ion fluence is at a rate of less than 1012 ions/cm2 the mode of 
operation is considered to be “static” SIMS. By reducing the fluence, the technique 
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interrogates only the top most atomic or molecular layers of a target material of interest 
to reveal both elemental and chemical composition. The energy from the primary ions is 
dissipated near the surface region of a solid allowing for a minimally destructive process 
(<1% surface damage) with minimized beam mixing and beam damage issues. 
Furthermore, using static SIMS it is possible to relate information in nanovolumes by 
looking at the area perturbed.103  When the fluence of primary projectiles is statistically 
below ~1000 ions/s each projectile impact is isolated in time and space. This is better 
known as the “super static regime” and allows for stochastic analysis. Stochastic 
sampling allows for better consistency and quality of secondary ion information 
collected. The secondary ions from each individual impact event are collected and stored 
before the subsequent projectile perturbs the target. This methodology is termed as the 
event-by-event bombardment detection mode. The “event-by-event 
bombardment/detection mode” probes nano-objects one at-a time, while collecting and 
storing the corresponding secondary ion information.104  Having a lower fluence with a 
relatively small primary ion greatly limits the amount of information revealed due to the 
relative inefficiency of the projectile in the production of secondary ion signal. The 
challenge was to increase the emissions of intact molecular ions. This however changed 
with the use of cluster (polyatomic) projectiles. 
 
Cluster SIMS  
 In 1960 Rol et. al. and Gronlung et al. observed that impacting metallic surfaces 
with a small cluster such as KI+ lead to larger secondary ion sputter yields compared to 
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individual ion beams of K+ and I- alone.105, 106 By using SF6 polyatomic cluster ion an 
ion yield enhancement of ~10-25 folds was observed by Appelhans et al. in 1989 in 
comparison to the yields reported by using Cs+ ions despite their similar atomic masses. 
107 The main observations from cluster SIMS include a) nonlinear increase in secondary-
ion yields with complex cluster projectiles; and b) increase of secondary ion yields 
proportional to the square of the projectile velocity for atomic species.108  
 In 1996 E.A. Schweikert et al. reported that 20 keV C60
+ cluster projectiles 
produce a ~17 fold enhancement for phenylalanine molecular yield compared to Cs+ and 
Ga+ projectiles at the same impact energy.109 Vickerman et al. developed a 10-15keV 
C60
1,2+ effusion source that enhanced the secondary ion yields for gramicidin A among 
other materials when compared to Ga+, Au+ and Au3+ primary projectiles.110, 111 The 
source lead to several major innovations in depth profiling112, 113 due to decrease in the 
damage cross sections and was commercialized shortly after. For several of the 
experiments discussed in this dissertation a similar custom built C60
1, 2+ effusion source 
built in the Schweikert lab at Texas A&M University was used to perform several of the 
experiments. 114, 115In 2004, Tempez et al. report the production of massive Au cluster 
projectiles ranging from Aun
q+ where n =1-1000, q=1-10 produced using a liquid metal 
ion source (LMIS).116 On bombarding a variety of peptide samples with Au400
4+ they 
observed a ~1000 fold yield augmentation compared with monoatomic gold projectile. 
Furthermore, the damage cross sections observed for Au400
4+ in comparison to Au5
+ and 
Au9
+ ions were significantly decreased. Another interesting outcome was the production 
of Au-analyte adducts using the Au400
4+ projectiles lead to enhanced secondary ion 
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information in comparison with the Au5
+ projectiles. In order to explain the 
enhancements observed using cluster projectile bombardment Bitensky and Parilis 
proposed the shock wave mechanism. They propose there is a “clearing the way” 
effected observed due to the stopping power of the impact of the first atoms in the 
cluster projectiles.117     
 At the Insitute de Physique Nucleaire d’Orsay Della Negra coupled a Au LMIS 
with a time of flight mass spectrometer to produce high energy Au400
4+ projectiles. 
Schweikert et al further developed this source to allow for single-impact events as 
opposed to a focused Au400
4+ focused beam. Although this source has not yet been 
designed to allow for imaging experiments this type of source may have major 
implications for imaging in the future due to potential impact on the spatial resolution 
being limited solely by the lateral extent of the surface area influenced by the single 
impact event. It has been proven to determine the nanoscale homogeneity of poly styrene 
cast on alumina whiskers within single impact sites.118 Experiments at the Schweikert 
lab also indicate that the interaction between the Au400
4+ projectile and substrate occur 
via hydrodynamic penetration which is different from the overlapping collision cascade 
effect. The interaction involves an extreme pressure transient at the interface of the 
colliding solids that lasts for a few picoseconds.119 Several physical phenomena such as 
impact light flash, ejection of matter and crater formation are all involved in the 
process.119 The latest addition to the Au instrument includes the incorporation of a 100 
keV Pegase acceleration platform to generate Au400
4+ projectiles with impact energies of 
up to 130 qeV with a target negatively biased target at 10 keV(Figure I-11).120, 121      
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 While cluster SIMS by and large has been widely accepted in the use of organic 
and polymeric material analysis, cluster sources have not been used extensively for 
inorganic material analysis. In some cases, there can even be disadvantages in the use of 
some cluster sources (e.g. C60 sputtering of Si).
122 In this dissertation, some novel sample 
depositions and preparation techniques have been discussed to overcome many of these 
challenges.  They have been employed with some success to allow for SIMS analysis to 
optimistically become more main stream in the analysis of inorganic nanomaterials. 
 
Coincidence Ion Mass Spectrometry  
 Coincidence counting has been an important technique in the field of nuclear 
science for some time now.123 Nuclear scientists monitor coincidental emission yields 
from radio isotopic decays. A typical coincidence experiment involves the detection of 
several distinct emission events simultaneously from a specific event. The concept 
however is a relatively unique one for the realm of mass spectrometry. Coincidence ion 
mass spectrometry or CIMS provides statistical correlations of secondary ions emitted 
from a single primary projectile impact from a conventional SIMS analysis.124 The 
secondary ion yields derive directly from the emission volumes of a single projectile (an 
area typically 10-20nm with a 5-10nm depth), coincidentally emitted ions must also 
originate from the same nanovolumes thus allowing for effective nanoscale analysis. The 
first reported use of CIMS in mass spectrometry was conducted by LeBeyec at al. in 
1983. They introduced the concept of colocalization within a 5-10 nm diameter crater  
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Figure I-11: (a) Schematic of the instrumental setup with both C60 effusion source 
and Au liquid metal ion source (LMIS) capable of detecting co-emitted photons, 
electrons and secondary ions from a single projectile impact. (b) Image of the 
Pegase 120 qkV platform (Au-LMIS). Top and bottom images in (b) electron 
images as seen in EEM phosphor screen for continuous Au400 beam. (Adapted from 
Reference 121)   
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with a single projectile impact and used it to study metastable secondary ion decay.125 
Schweikert and coworkers used CIMS for the first time to analyze NaF crystals and 
describe its chemical homogeneity.124 However, literature on this subject still remains 
relatively sparse. 
 To better understand material morphology and chemical homogeneity of a 
sample by monitoring secondary ion emissions, CIMS is a very useful tool. By 
performing CIMS analysis in the event-by event bombardment detection mode it is 
possible to note colocalization between secondary ions as well as with electrons 
produced from each individual projectile impact. This allows for real “nanoscale” 
analysis. This dissertation will discuss experiments operating in the event-by-event 
bombardment detection mode using C60
1, 2+ (26, 43 keV) and Au400
4+ (520 keV) 
projectile impacts to facilitate quantitative and qualitative analysis of complex inorganic 
layered material systems in the realm of surface characterization and drug delivery 
applications. CIMS has been used most recently by the Schweikert lab to quantitatively 
analyze nano-objects,104, 126-128 observe coincidental emissions of electron, photon and 
secondary ions129 and for electron mapping of secondary ions.130, 131    
  
 Current SIMS Analysis in Drug Delivery  
 This section describes some of the current trends in the use of ToF-SIMS to 
describe and interrogate drug delivery systems. Physical and chemical characterizations 
are an essential part of developing dosage strategies in pharmaceutical actives. The 
distribution of an active pharmaceutical within a solid state matrix is of extreme value as  
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it plays a crucial role in determining solid state stability and the drug-release profile. 
Raman and EDS have been applied extensively in the past to interrogate drug 
distribution within solid matrices; however both suffer from relatively low levels of 
surface specificity it (Table I-1).96 In comparison, techniques such as XPS and ToF-
SIMS offer a significant improvement in surface sensitivity. SIMS is becoming 
increasingly more prominent in the analysis of drug delivery systems due to three major 
facts: (a) low detection limits, (b) high spatial resolution and (c) high degree of surface 
sensitivity.  It has been employed extensively especially in the past decade in the 
characterization of organic and polymeric materials. Several common biomedical 
polymers and film coatings have been studied extensively using ToF-SIMS.132-136 In 
2000 Belu and coworkers report the use of ToF-SIMS in the analysis of a multilayer 
drug bead assembly. They reveal the layer-by-layer polymeric matrix-drug assembly 
revealing specific molecular ions for each investigated drug.89 While there has been 
considerable research in polymeric drug delivery matrices using ToF-SIMS, the 
literature on inorganic drug delivery systems such as LDHs, ZrP etc. has been scarce. In 
order to fill in some of those gaps, this dissertation seeks to find new and improved ways 
to characterizing the ILN zirconium phosphate in its applications for drug delivery. The 
information revealed from SIMS is used to design specific pharmacokinetic release 
studies and subsequent in-vitro release in a cellular environment.    
 It is highly desirable to correlate solid-state drug distribution within a pre-
existing delivery matrix with the dissolution and pharmacokinetic drug release in order 
to be able to design more effective delivery matrices.       
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CHAPTER II 
INSTRUMENTATION AND METHODOLOGY 
 
This chapter describes in some detail the instrumentation including hardware, 
detection and supporting electronics utilized in performing the secondary ion mass 
spectrometry studies as part of the research in this dissertation. A C60 effusion source 
and Au liquid metal ion source coupled with time of flight mass spectrometry has been 
used to perform the previously mentioned studies. Also, the methodology developed to 
conduct quantitative nano-analysis of inorganic layered materials in both surface 
analysis and drug delivery is introduced in detail in this chapter.  
 
C60 Effusion Source Mass Spectrometer  
 It is important to note that the instrumentation discussed is a custom built unit 
from the Schweikert lab at Texas A&M University. A schematic of the C60 source 
coupled to a time of flight mass spectrometer is shown in Figure II-1.137 The instrument 
consists of two main ion legs. The primary and secondary ion legs are separated via a 
gate valve. The source operates under a vacuum pressure of ~5 X10-6 torr with a turbo 
pump (60 L/s – Pfeiffer Vacuum Inc., Nashua, NH) and two-stage rotary vane 
mechanical pump (3.7 L/s -Varian Inc., Palo Alto, CA). The C60 effusion source is 
housed in a custom-built stainless steel chamber. The design of the source contrived in 
the Schweikert lab uses a design template inspired by the Vickerman group.110, 111   
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 The source contains neutral C60 powder (Sigma Aldrich, Milwaukee, WI) packed 
into a copper reservoir and heated upto 450 ºC (3.9 Amp) to initiate C60 sublimation 
(Figure II-2).138, 139 The resulting C60 vapor is channeled through an aperture in the 
reservoir into an ionization reservoir into an ionization (Figure II-2). The resulting C60 
vapor is channeled through an aperture in the reservoir into an ionization chamber. A 
tungsten wire (0.1 mm diameter, Alfa Aesar, Ward Hill, MA) is positioned ~ MA) is 
positioned ~5 mm away with a 90 V potential drop from the cylindrical electrode. This 
electrode which is essentially a stainless steel tube is wrapped with a tungsten wire mesh 
chamber. A tungsten wire approximately 0.1 mm and 2 cm in length in diameter (Alfa 
Aesar, Ward Hill, approximately 0.01 inch in diameter (Alfa Aesar, Ward Hill, MA). 
Upon heating this tungsten framework the resulting thermally induced electrons are 
accelerated towards the electrode to impact the C60 vapor that has been channeled into 
the region thus resulting in the ionization of the C60. The mesh covering the cylindrical 
electrode is grounded thus allowing for a -90 V gradient potential. This facilitates the 
acceleration of electrons from the filament towards the cylindrical electrode. 
 The resulting C60 ionized species are extracted with a potential gradient (0.5 kV) 
between the source which is maintained at16 kV and the extraction plate maintained at 
15.5 kV. Electrostatic lenses are used to accelerate and focus the resultant cationic 
species. By employing a Wien filter the mixture of C60 cations are sorted and mass 
selected for a specific primary ion of interest (discussed in some detail in the following 
sections). The selected C60
+ primary projectiles are then verified by pulsing the beam 
over an aperture and measuring its time of flight. Any neutrals resulting from the 
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procedure remain unaffected by the steering potential or Wien filter mass selection. In 
order to remove any neutral species from the mix an off-center aperture (~ 1mm in 
diameter) is categorically positioned past the Wien filter. While the mass selected C60
+ 
are steered past this aperture the neutral species remain on an unaltered path thus 
effectively being extracted away from the target.  
 The main chamber of the C60 TOF-SIMS instrument is maintained at ~2 X 10
-6 
torr using a diffusion pump (760 L/s, BOC Edwards Vacuum, Tewksbury, MA) backed 
with a two stage rotary vane mechanical pump (5 L/s, Alcatel Vacuum Product, 
Hingham, MA). The sample inlet chamber is segregated from the main chamber via a 
gate valve and maintains a vacuum of ~5 X 10-6 torr during sample introduction. The 
total impact energy of the C60
+ primary ions is 26 keV. The primary ions are extracted by 
applying 16 keV to the effusion source and a 10 keV potential drop is applied to the 
negatively biased target. 
 Once past the collimating aperture, the C60
+ primary projectiles are steered 
towards the negatively biased target with a set of horizontal and vertical plates. Upon 
impact with the negatively biased target the C60
+ projectiles lead to the production of 
secondary ions, electrons, photons and neutral species. By applying a magnetic field (< 
100 Gauss) the resulting electrons are deflected towards a start detector that consists of 
microchannel plates (MCPs) arranged in the chevron formation. This detected signal 
motions as the start of a collision event. The simultaneously ejected secondary ions 
travel through a field free time of flight drift tube (92.9 cm in length) towards a 
grounded grid (90% transmission, attached in front of the time-of-flight tube). This 
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results in a -10 keV potential gradient. The secondary ions are detected by an 8-anode 
detector as the stop signal for the time of flight event.  
 This 8-anode detector consists of 8-separate copper plates assembled with a dual 
MCP assembly. The detector can simultaneously record upto 8 distinct ions with the 
same flight time striking the MCPs. The distribution of the detected species can be 
monitored using an in-house data acquisition program. In order to optimize the 
distribution of the secondary ion detection, voltages maybe applied onto the respective 
steering plates to change the position of C60
+ primary ion impact. The upkeep and 
maintenance of the C60 effusion source has been described in detail elsewhere.
137       
 
Au Liquid Metal Ion Source Mass Spectrometer                        
 A detailed description of the instrument is available elsewhere.140, 141 In brief, the 
instrument consists of a primary ion leg where the pressure is maintained at less than 1 X 
10-6 torr using a turbo pump (400 L/s, Adixen, ATP400, Alcatel Vacuum Technology 
France) and backed by another mechanical pump composed of 5 root type stages 
(Adixen, ACP28, Alcatel Vacuum Technology France). A schematic of the instrument is 
shown in Figure II-3.139 The primary ion leg is where the primary ion generation and the 
subsequent delivery of the cluster projectiles to the target surface takes place. It consists 
of a gold liquid metal ion source (Au-LMIS) focusing lenses, Wien filter and pulsing 
plates. The length of the primary ion leg is approximately one meter from the LMIS to 
the target.     
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The Au-LMIS was originally developed by Serge Della Negra and coworkers at 
the Institute de Physique Nucleaire d’Orsay (IPN in Orsay, France) and the mass 
spectrometer was assembled in the Schweikert research lab at Texas A&M University.  
It consists of a tungsten spring reservoir consisting of a tightly wound tungsten coil with 
approximately 8-10 turns and a tungsten needle (0.2 mm diameter; 20 mm length). Refer 
Figure II-4 for a schematic.140 The needle is electrolytically etched to have a ~90º angled 
tip and arranged centrally within the confines of the coiled reservoir. This is done to 
facilitate the formation of a Taylor cone, in which case the Au clusters are emitted from 
the tip of the needle during primary ion extraction. The reservoir and needle assembly is 
then dipped into a Au-Si eutectic (97% Au, 3%Si by mass, Academy Precious Metals, 
Albuquerque, NM). Primary ions are extracted by heating the Au/Si eutectic to its 
melting point (~363 ºC) and applying an extraction potential (6.9-7.4 kV) between the 
needle tip and the extraction electrode (0.5 mm away). The fabrication of the Au-LMI is 
The fabrication of the Au-LMIS is detailed in these references.141, 142The Au-LMIS is 
floated at 20 keV relative to the platform providing primary ions with 120 qkeV total 
kinetic energy. The resulting Au projectiles are then accelerated to 130 qkeV to impinge 
upon the negatively biased target (10 keV). The LMIS emits a wide range of gold 
projectiles Aun
q+ ranging anywhere from 1 ≤ n ≤ 1000 and 1 ≤ q ≤ 10. The projectile 
beam is focused using an einzel lens assembly. The details for the einzel lens potential 
adjustment for this instrument can be found elsewhere.141 The beam current, which is 
measured using a Faraday cup without pulsing is measured to be ~200 nA. Post 
focusing, the projectile of interest is mass selected using a Wien filter (discussed further  
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in following sections). The mass selected projectiles are then deflected onto a pair of 
collimators where they pass through. These collimators have a variable set of apertures 
ranging from 5mm, 1mm, 500μm and 200μm. The projectiles are steered by applying 
voltages to the primary ion deflection plates and passing through the second collimator 
before entering the pulsing system.  
The beam is pulsed in order to provide a start signal for the primary ion time of 
flight so as to verify the mass to charge ratios of the particles. The second reason for 
pulsing is to reduce the beam flux so as to enable event-by-event 
bombardment/detection. The pulsing system consists of a set of horizontal and vertical 
plates (-1 keV to +1keV at 3 kHz). Subsequently, the primary projectiles are steered 
towards an exiting variable aperture (200µm, 500µm or 5mm) to finally impinge upon 
the negatively biased target at -10keV. To assure only a single Au400
4+ projectile 
impacts, a fluence of 1000 primary ions per second is set. Post interaction the electrons 
that are produced as a result are deflected onto a MCP assembly to capture the start 
signal, a lot like the previously mentioned C60 instrument. The secondary ions produced 
simultaneously are accelerated towards a grounded grid at which point the secondary 
ions enter the field free drift region. This maybe linear or reflectron time-of-flight 
analyzer. The secondary ions are detected by a dual MCP assembly and an 8-anode 
detector(Figure II-5). By changing the voltages of the horizontal and vertical steering 
plates it is possible to alter and adjust the monitoring of the secondary ion distribution.  
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Time of Flight Mass Spectrometry  
 Both the C60 and Au-LMIS instruments work on the principles of time of flight 
for the mass analyzers used in the course of the experiments discussed in this 
dissertation. Using a time of flight mass analyzer ensures that all the events are sampled 
when compared to other techniques such as quadrupole mass filters, magnetic and 
electric sector instruments, in case of which greater than 90% of the ions, go 
undetected.143 ToF mass analysis is possible because temporal separation occurs in a 
field free drift region of ions having the same kinetic energy, but different masses and 
therefore different velocities.140 
 The secondary ions that are produced are influenced by two distinct regions that 
directly affect its recorded time of flight. The first is the acceleration region (Figure II-
3). The time it takes to traverse this regions, ta, is:  
          √
   
 
  
√
 
 
                    Eq.II-1 
where La is the length of the accelerating region, Va is the bias applied in the 
acceleration region; m is the mass of the ion with a charge q. Once past the acceleration 
region the secondary ions will now encounter the drift free region. The time taken by the 
ion at this juncture can be calculated as follows:  
       √
   
 
   
√
 
 
                     Eq II-2 
50 
 
Where Ldr is the length of the drift free region. The last contributing factor for the total 
time of flight is the deceleration region Ld with the application of a high voltage bias Vd, 
the time taken to traverse this region maybe calculated as follows:  
    
  
 
  
√
  
 
(√       √  )        Eq. II-3  
 Thus bringing the total time of flight for the ion to ttot: 
                 √ √
 
 
(√
  
 
  
 
 
 
√
  
 
  
 
  
 
  
(√      √  ) )     
Eq. II-4 
A more detailed explanation for these derivations have been discussed elsewhere.100, 102, 
103, 105  
 Once the spectrum is collected it must be mass calibrated. Knowing that the 
flight time, ttot, of an ion is proportional to the square root of its m/q ratio, all other 
factors can be reduced to two constants giving rise to the following:  
     √
 
 
            Eq. II-5 
Where C1 is a constant determined by the sample bias and flight length and C2 is 
determined by the speed of the timing electronics.124, 144 Out of all the unknowns if the 
identities of at least two ions are known, then it is possible to solve a system of two 
equations for C1 and C2 to calibrate the entire spectrum. A more precise determination 
can be made through iterative determinations of C1 and C2. 
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 The mass resolution, is the capability of the mass spectrometer to distinguish two 
peaks of slightly different mass-to-charge ratios ∆m, in a mass spectrum. The mass 
resolution, R, for a mass spectrometer can be defined as:  
   
 
  
 
 
   
       Eq. II-6 
Where m is the measured value at the center of the peak at mass m; ∆m is measured at 
the full width at half maximum (FWHM). The mass resolution for the studies presented 
in this thesis is ~600 at m/z 74. 
 
Detectors and Detection Electronics  
 Once the electrons and secondary ions are emitted the signals from them are 
amplified by striking a microchannel plate (MCP) (Photonis, Pittsfields, MA) assembly. 
Microchannel plates are generally lead-doped glass electron multiplier microtubes 
(dynodes) set in parallel arrays. The outside diameter of the MCPs for secondary ion 
detectors is 50 mm with the active area ~40 mm in diameter and a thickness of 0.46 mm. 
Fused together, they form a thin plate which can be used singly or stacked together. 
When the electrons or secondary ions interact with the microchannel plate an electron 
cascade is formed, resulting in a ~103 gain across a single MCP. In the detector 
assemblies used in the mass spectrometers here (Figure II-6), MCP’s are used in 
Chevron formation.143 The total assembly consisting of two microchannel plates is ~106.  
 The electron cascade that results from a particle impact on the MCP assembly is 
collected at the exit of the MCP using a copper anode. In the case of the electron 
detector, a single copper plate is used as a “single anode” collector. The stop detector for  
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the secondary ions consists of an 8-anode detector allowing for upto 8 isobaric ion 
detection per event. The 8-segment collector made from a copper plated circuit board is 
discussed in detail elsewhere.140 A newly modified anode was installed on the C60 
instrument.139 Using an 8-anode detector ensures that each anode registers equal 
amounts of ions and the detector therefore achieves the maximum detection capability. 
This results in a detection efficiency of ~40% for the experiments performed in this 
thesis.143   
 
Signal Processing 
 The electron flux once collected by the anode is processed by a quad CFD 
(Tennelec, Meriden, CT). The output signal from the SI detector is passed to an octo-
port CFD (Ortec, Oak Ridge, TN). The CFD transforms the negative voltage pulse from 
the anode into a NIM (Nuclear Instrumentation Module - square wave) pulse which 
proceeds to the time to digital converter (TDC).142 The CFD helps set a threshold for 
signals allowing only those above a certain limit to pass onto the TDC for processing. 
The TDC has one input for the “start” signal and 8 “stop” signals. The start signal 
initiates a data acquisition window during which stop signals are collected. The TDC 
converts the NIM pulse to a digital signal which is recorded. The digital output is 
processed by the “Total Matrix of Events” (TME), which is an in house processing 
software described in depth elsewhere.141 This software helps draw relationships 
between individual emission events as well as calculate secondary ion yields.  
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Event-by-Event Bombardment/Detection Mode 
 The key defining feature for the mass spectrometry methodology used in these 
experiments is the use of the event-by-event bombardment/detection mode. Single 
projectiles impact the target surface and the resulting secondary electrons and ions are 
collected as individual “events”. As noted earlier, the sampling is performed in a 
stochastic manner ensuring the same spot isn’t sampled more than once. Each cluster 
impact causes a nanovolumetric impact crater. The fragmented secondary ions are co-
ejected after each projectile impact and are resolved separately in time and space as 
“singular” events. An event is defined by a single projectile impact, the detection of the 
resulting electrons as the start and subsequently detecting the resulting secondary ions. 
For a typical experiment anywhere over a million events are collected. The Schweikert 
lab employs the concept of coincidence counting in conjunction with ToF-SIMS for 
further analysis. Park et al report some requirements for coincidence counting:    1) in 
order to spatially distinguish the components of the samples the sampled regions should 
be small; 2) each component of the sample must generate distinct secondary ions to 
enable chemical distinction. In the case of samples bombarded by the C60
+,2+ and Au400
4+ 
projectiles, the volume from which secondary ions are emitted is ~103 nm3. Using the 
event-by-event bombardment detection it is possible to identify co-located species 
within nanodomains using coincidental ion mass spectrometry. From the coincidence ion 
mass spectrum the co-emissions can be deconvoluted from the cumulative secondary ion 
mass spectrum (seen in Figure II-6). Once individual ions from complex surfaces are 
identified, using coincidental ion mass spectrometry. The coincidental emission intensity  
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of two specified  ions allows for a variety of applications in the quantification of surface 
immobilized species(Figure II-7). In this dissertation, the concept of coincidental ion 
mass spectrometry is applied to quantify the surface modification of nanomaterial. 
Before addressing the concept of the quantitative analysis, the correlation coefficient is 
defined below. 
 
Correlation Coefficient  
 In nuclear science correlation coefficient is a widely employed concept using 
coincidentally detected signals.123 The yield of the detected ions A is computed as in Eq. 
II-7: 
   
  
  
           Eq. II-7 
IA is the measured peak area under ion A. NT is the total number of projectile impacts 
sent to bombard the target surface  Coincidental yields can be experimentally determined 
for two ions, A and B, given: 
    
   
  
           Eq. II-8 
Where YA,B is the coincidental yield for ion A coemitted with ion B, IA,B is the 
experimental relative intensity for ion A in coincidence with ion B. The secondary ion 
yield is expressed as follows:  
    
   
    
             Eq. II-9  
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YA and YB are the secondary ion yields of the detected ions A and B respectively. The 
correlation coefficients Q correlated to the spatial homogeneity of chemical species are 
summarized as follows: 
Q = 1, the emission of two coincidental ions A and B originated from a nanovolume is 
uncorrelated, i.e., when ions A and B are emitted independently, the probability of the co 
emission is equal to the product of each individual emission/detection probability. 
Q > 1, the emission of ions A and B is correlated, i.e., the emission of ion A enhances 
the emission of ion B. 
Q < 1, the emission of ions A and B is anti-correlated, i.e., the emission of ion A 
suppresses the emission of ion B. 
 
Quantitative Methodology  
 The concepts of fractional coverage and material homogeneity are applied to 
some of the studies discussed in the course of this thesis. They are used to identify the 
quality of immobilized molecules on the surface of nanomaterials and the physical 
assemblies of complex layer by layer drug-nanomaterial assemblies. The quantitative 
methodology, extent of surface coverage is in terms of the ratio of the number of 
effective impacts in specific species to the total number of projectile impacts sent to 
bombard the target surface. The sample preparation procedures used to fabricate the 
sample depositions in each of the studies is described in detail in the next chapters.    
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CHAPTER III 
SURFACE FUNCTIONALIZATION OF ZIRCONIUM PHOSPHATE 
 
Introduction  
The modification of platforms with multiple molecules or containing molecules 
with varied functional components has become increasingly popular in the past two 
decades.145  When it comes to the characterization of morphologies in the nanometric 
scale there is a general consensus that more needs to be done to improve the 
characterization of these materials.16, 17 Considerable effort has been devoted to the 
design and controlled fabrication of nanostructured materials with functional properties. 
The ability to control the surfaces with high precision and level of control has led to the 
need for characterizing these molecular constructs by which the surfaces are modified. 
Effective strategies to build tailored nanomaterials reliably and predictably are required 
in order to meet the ever-increasing demands (e.g., structural and compositional 
complexity) placed on materials synthesis and performance by nanotechnology.146 
Surface tethered molecular components can serve a multitude of scopes, including 
coupling biomaterials,2 allowing electron transfer through layers,3-5 sensors and 
biochips,6, 7 drug delivery,8-10 photovoltaics,12, 13 fuel cell,14 and molecular electronics,2, 
12, 15as well as controlling reactions at surfaces,5 and tailoring surface properties.147 
Zirconium phosphates (ZrP’s) are the ideal class of sophisticated acidic, 
inorganic cation exchange materials for surface modification reactions. The ease of 
synthesis, of crystallinity and size control has allowed for α-ZrP to be used as the model 
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system for intercalation and surface modification chemistry studies for over four 
decades.148-151 The tunability of the size, morphology and aspect ratios30 of ZrP has 
opened up a wide range of applications11, 40, 45, 152-158 through the immobilization of 
organo and metal-based modifiers. By custom designing the surface of the ZrP for 
specific applications, its applicability in the realm of catalysis, drug delivery, as 
polymeric surface interfaces among many others can be greatly enhanced. Establishing a 
technique to monitor the surface coverage can help maximize the respective application 
properties. 
This chapter reports the surface modification of the α-phase of the ZrP with a 
host of different modifiers based on the reaction of the surface which consists of 
parallelogram arrays of P-OH groups. This was monitored and followed using secondary 
ion mass spectrometry (SIMS) in the event-by-event bombardment mode using the 
custom built C60
+ instrument described in the previous chapters in conjunction with 
thermo gravimetric analysis (TGA), infrared spectroscopy(IR), nuclear magnetic 
resonance spectroscopy (NMR), microprobe analysis and x-ray powder diffraction 
(XRPD) techniques to determine the quality and tentative degree of surface coverage. 
Although the exact bonding arrangement was not immediately apparent the quality of 
surface coverage was easily identified using these techniques in conjunction. The 
evolution of self-assembly techniques for surface modification has led to a wealth of 
research on the construction and applications of nanostructures thin film materials.  
Previous investigations have demonstrated that inorganic particles dispersed in 
aqueous solutions can be coated with a variety of organic and inorganic materials either 
60 
 
by precipitation of the coating material, or by direct surface interaction through covalent 
bonding utilizing specific functional groups on the cores to induce coating.159, 160 The 
layered compounds obtained in this manner are considered organic derivatives of the 
parent. It is possible to change the hydrophobic/hydrophilic character of the surface of 
the material by interspersing the inorganic P-OH groups with suitable organic 
modifiers.161 
The structure of α-ZrP has a layered configuration in which the Zr ions are 
slightly above and below the mean plane of the layer. Three of the monohydrate 
phosphate oxygen atoms bond to three adjacent Zr ions with phosphate groups 
alternating above and below the plane. The remaining OH groups points out toward the 
interlammelar space. A very attractive aspect of zirconium phosphate chemistry is 
related to the possibility of replacing the P-OH groups anchored to the layer surface with 
P-OR or P-R groups without altering the inorganic texture of the layer (R is an organic 
group).162 Schematic representations of α-ZrP are provided in Figure III-1.   
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Experimental Section  
 
Materials 
In this study all the chemicals were purchased from Sigma-Aldrich Chemical Co. 
and used as received with the exception of phosphoric acid, 85% (v/v) (H3PO4), which 
was purchased from Fisher.  
 
Synthesis 
The synthesis of the ZrP nanoparticles was performed by following the procedure 
outlined by  Kijima in 1982.163  200 mL of 0.05M ZrOCl2.8H2O aqueous solution was 
added drop wise to a 200mL solution of H3PO4 (6M) preheated to 94°C. The resulting 
solution was refluxed for 2 days. The product was washed several times with deionized 
water and dried at 70°C resulting in a powder which is ground up and characterized by 
XRPD, FTIR and TGA, SIMS, NMR and depth profiling respectively. 
The surface modification of the α-ZrP nanoparticles was carried out by 
suspending the nanoparticles in hot toluene at 75 °C for the 3-(triethoxysilyl) propyl 
isocyanate (TEPI), dichloromethylsilane (DCMPS) modifications for 1 h under constant 
stirring and switching between vacuum and N2 atmosphere in a Schlenk line with a 
condenser attachment, to eliminate all the water from the surface of the α-ZrP. A 
solution of each respective modifier was dissolved in toluene (200 mL final volume) and 
was then added (1:10 TEPI/ZrP & 1:10 DCMPS/ZrP molar ratio) and reacted with the 
“dry” α-ZrP suspended in the toluene for 12 h. The product was washed several times by 
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centrifugation with dry hexanes, and then with a mixture of hexanes and ethanol. The 
final product (TEPI/α-ZrP & DCMPS/ α-ZrP) was dried at 80 °C for 24 h. The lauryl 
methacrylate (LMA) reaction was performed in a round bottom flask in hot hexane at 75 
°C for 12 hours in a 7:1 LMA/ α-ZrP molar ratio with a condenser attachment. The 
resulting product was treated the same as the other two modifications (vide supra).    
 
Instrumentation  
Once the materials were synthesized the complete characterization of the 
materials was performed using several analytical techniques. X-ray powder diffraction 
(XRPD) patterns were collected with a Siemens D8 diffractometer using CuKα 
radiation (1.5418 Å) at 40 kV and 40 mA with a filtered flat LiF secondary beam 
monochromator. The measurements were recorded from 2–40° (2θ range). Bragg’s law 
was applied to the (002) diffraction plane of the    α-ZrP diffraction pattern to determine 
the interlayer distance. According to Bragg’s Law the distance (dhkl) between planes 
(hkl) is equal to the ratio between the wavelength of the source and 2 times the sine of 
the diffraction angle, or as is expressed in the equation of the Law: 
     
 
     
        Eq. III-1 
Thermogravimetric analyses were performed with a TA Q500 instrument. The 
temperature was ramped at 10 °C min–1 under a flow of air/N2 9:1 up to 1000 °C.  
Quantitative compositional analyses were carried out on a four spectrometer 
Cameca SX50 electron microprobe.  Analyses were run at an accelerating voltage of 15 
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kV at a beam current of 20 nA. All quantitative work employed wavelength-dispersive 
spectrometers (WDS).  Analyses were carried out after standardization using very well 
characterized compounds or pure elements. Qualitative analyses (spectra) were obtained 
with an Imix Princeton Gamma Tech (PGT) energy dispersive system (EDS) using a 
thin-window detector. 
Typical accuracy for major elements (> 10 wt. %) is about =+/- 1 to 2 % of the 
amount present; the uncertainty at low concentrations would increase as the 
concentration decreased, with the uncertainty reaching 100% at the lower limit of 
detection (LLD).  The lower limit of detection for most elements under typical 
conditions would usually be about 0.05 to 0.10 wt. %.  Pressed powder samples will 
have some additional uncertainty based on surface roughness.  The main effect of 
surface roughness will be to reduce analytical totals because of X-ray scatter.  However, 
X-ray scatter is also wavelength dependent, which could result in a few percent change 
in apparent elemental ratios if the surface is very rough and there are significant 
differences in wavelength. 
The secondary ion mass spectrometry measurements were carried out with the 
custom-built  instrument coupled to a 1 m linear time-of-flight (TOF) mass analyzer 
described in the previous chapter.164 The C60
+, 2+
 and Au400
4+ projectiles were used to 
perform the experiment in this chapter. The SIMS analysis for each of the samples was 
conducted in the super static regime, where less than 0.1% of the surface is impacted. 
This enabled stochastic sampling. The measurements were collected in the event-by-
event bombardment detection mode, meaning the secondary ions from a singular 
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projectile impact were collected and analyzed prior to the ensuing impact. All the 
collected secondary ion information is derived from ~5 nm excavation radius on the 
sample surface. Each sample interrogation consisted of ~1.5 × 106 projectile impacts on 
an area ~ 100 μm in radius thus, sampling several million particles stochastically to 
retrieve relevant surface information. Multiple measurements were performed to ensure 
sample consistency.   
The transmission electron micrographs (TEM) of the samples were acquired 
using a JEOL 2010 transmission electron microscope at an acceleration voltage of 200 
kV. Samples were prepared using copper grids from Ted Pella. The FTIR were 
performed using a Shimadzu IRAffinity-1 spectrophotometer in an ATR (attenuated 
total reflection) mode. 
 
Results and Discussion    
For each surface modification reaction the X-ray powder diffractograms for the 
pristine α-ZrP and the surface modified materials are compared in Figure III-2. To 
ensure the modification was solely sequestered onto the surface each of the three 
resulting products were monitored. The diffractograms reveal no significant alteration in 
the layer lattice arrangement of the α-ZrP in each of the three cases vs. that of pristine α-
ZrP. This is evidenced by the characteristic 002 diffraction peak at 7.6Å attributed to the 
α-phase in each case and the absence of diffraction peaks at lower angles.   
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The TEM images reveal no significant alteration in surface chemistry from that of 
pristine α-ZrP (Figure III-3) in the case of both TEPI (Figure III-4) and DCMPS (Figure 
III-5) modifiers, however the modifier LMA (Figure III-6) appears slightly altered.  
The FTIR patterns were monitored for all the modified materials and compared 
to the pristine α-ZrP to reveal respective characteristic stretches which have been 
summarized in Figure III-7. α-ZrP has two characteristic IR bands that correspond to the 
splitting of the crystallization water band at 3590 and 3510 cm–1, νas (OH),
165 which 
remains in the spectrum of the surface-modified materials in each case. This resonance 
becomes less intense when the adsorbed amount of modifier increases. It also confirms 
the XRD results showing that there was no intercalation or displacement of the 
intercalated water molecule. In addition, the FTIR spectrum of TEPI /α-ZrP shows the 
disappearance of the strong characteristic bands associated with the isocyanate band at 
2260cm-1 in the reaction product which maybe indicative of the reaction of the 
isocyanate group with the hydroxyphosphate on the surface of ZrP (Figure III-8a). 
Additionally the appearance of the secondary amine band at 3375cm-1 (Figure III-8b) 
along with the symmetric stretching of the C–H, between 2900 and 3000cm-1 in the 
reaction product also indicates modification.  
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The C=O amide band appears at 1685 cm-1 (Figure III-8c) in the reaction product and the 
secondary amide band at 1525 cm-1. The silane rocking and wagging also appears 
between 750 and 800 cm-1. (Figure III-8d).In the DCMPS/ α-ZrP the appearance of the 
silane rocking and wagging stretches between 750 and 850 cm-1 in the reaction product 
indicate modification (Figure III-9a). The appearance of the stretches between 1700-
1500 cm-1 indicate the addition of aromatic C=C bending onto the modified ZrP product 
(Figure III-9b).  
For LMA/ α-ZrP the emergence of the –CH2 stretching absorbance at 2900 cm
-1 
points to the possible addition of LMA onto the surface.166  The disappearance of the 
carbonyl peak between 1705-1730 cm-1 (Figure III-10b) indicates a possible bonding site 
for the LMA onto the surface P-OH groups and the possible polymerization onto the ZrP 
surface to form PLMA. The absence of the peak in the reaction product also indicates a 
lack of free or unassociated carbonyls. The other FTIR resonance at the lower frequency 
(roughly at 1710 cm-1) was from the carbonyl groups that were bound to the ZrP 
surface.166 It was discovered experimentally that the relative intensities of bound 
carbonyl compared with the free carbonyls decreases with an increase in the adsorbed 
amount of LMA hence the 7:1 molar ratio for LMA/ZrP was settled upon.     
The TGA for each surface modified material and its characteristic weight loss is 
elucidated (Figure III-11) and the overall extent of modification is estimated in each case 
in Table III-1. The TGA of all three modified materials shows an increase in the weight 
loss as compared with the pristine α-ZrP which has a typical weight loss of ca. 12%.3 
The first weight loss observed can be attributed to the loss in surface and intercalated 
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water molecules at ca. 120 °C. The next major weight loss is observed at ca. 540 °C and 
can be attributed to the formation of the pyrolysis product ZrP2O7. 
 The TGA for the TEPI /α-ZrP shows a weight loss of 17.3 %, DCMPS/ α-ZrP a 
weight loss of 14.2% and for LMA/ α-ZrP a weight loss of 19.51% with the appearance 
of additional weight loss points. In all cases the first weight loss at can be attributed to 
the cleaning solvents and surface moisture. The next weight loss at ca. 135 °C can be 
attributed to the loss of the intercalated water within the lattice structure for each of the 
materials. Due to the modifiers, accessing this water becomes harder hence why the 
temperature is higher in the modified compounds vs. the pristine ZrP in each of the three 
cases. Additionally, due to the varied lengths of the attached aliphatic chains and 
differences in individual functional groups in each of the three cases the next weight loss 
occurs between 250-425 °C. The final weight loss takes place ca. 525 °C and is 
attributed to the formation of the zirconium pyrophosphate due to the condensation of 
the phosphate groups. It is interesting to note that the LMA which we suspect is actually 
forming PLMA onto the α-ZrP surface reveals the biggest weight loss compared to the 
other two modifiers. This last weight loss attributed to the condensation of the phosphate 
groups is decreased by 15 °C when compared to that of the pristine α-ZrP, probably 
because of the pyrolysis of the aliphatic chains causing damage to the crystal structure of 
the ZrP particles, allowing a faster thermo decomposition.3   
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The surface modification for the ZrP nanoplatelets were monitored by the 
substitution of the surface phosphate groups and further confirmed by microprobe 
quantitative compositional analyses (Figure III-11& III-12) and ICP-MS (Table III-2). 
The amount of silicon in the surface modified products can be easily monitored in the 
case of both TEPI-ZrP and DCMPS-ZrP. Since LMA doesn’t offer any easily 
identifiable species it wasn’t analyzed using microprobe or ICP-MS analysis.  
Event-by-event cluster SIMS was performed on each of the surface modified 
samples to probe the effective surface coverage and to determine both qualitatively and 
quantitatively if a chemical modification event was occurring. A quantitative estimate of 
surface coverage of modifier (TEPI,DCMPS or LMA) containing molecules was 
calculated for each sample by using the coincidence counting technique by comparing 
the signals attributed to modifier m/z indicated in the respective mass spectra in color 
(Figures III-13,14 & 15), corresponding to each respective modifier anion, and m/z = 79 
or 63, corresponding to PO3
- or PO2
- anion, with the signal of  “coincidentally 
emitted/detected” surface modifier and PO3
- or PO2
- anions.167  A quantitative estimate 
of TEPI, DCMPS & LMA surface coverage was calculated,167 
following eqn(1) and (2), where it was determined that the TEPI coverage is 45.2% ± 
2.8%, DCMPS coverage is 20.85% + 2.3% and LMA coverage is 94.9% + 2.5%.    
          
                          
                                
       Eq III-2 
          
  
  
       Eq. III-3 
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Sample P (ppm) Si (ppm) Zr (ppm)
DCMPS-ZrP 155 8.03 228
TEPI-ZrP 156 10.1 201
Figure III-12: Microprobe analysis X-Ray Spectrum of (a) DCMPS-ZrP  
(b) TEPI-ZrP from 800 μm area 
(a) 
(b) 
Table III-2: Elemental concentrations for surface modified ZrP nanoplatelets.   
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One benefit of using the event-by-event bombardment/detection mode is the ability to 
obtain more insight into specific impact/emission events. In order to obtain a 
representative mass spectrum for a given component of the system, the co-emission from 
that component may be displayed in a coincidence mass spectrum. For example, in order 
to obtain a representative mass spectrum from the modifier domain, all ions coemitted 
with Cl- are monitored for the DCMPS modified α-ZrP. Projectile impacts resulting in 
chloride emission also showed emission from hydrocarbon peaks and silicon oxide 
peaks. The most intense peak in the coincidence spectrum is m/z 77 SiO3H
- (coincidence 
yield = 3.5x10-5), which implies that chloride-rich areas of the modified α-ZrP are less 
than 10 nm in thickness. In the previous chapters the equations for calculating surface 
coverage were briefly discussed. Calculating NE gives the fraction of relevant modified 
ions and compares that with No which is the total number of projectile events. 
 Subsequently, the calculated experimental coverage for each of the surface 
modified ZrP were compared to their maximum theoretical coverage. For the TEPI-ZrP 
if the bonding occurs through the amino group it would be placed midway between the 
two P-OH groups and held in place by a hydrogen bond. The hydrogen bonding is (P)-
O-H--N-H--O-H—N, etc.168 This is similar to the hydrogen bonding in α-ZrP between 
the P-OH groups and water.169 If all the possible P-OH sites on the ZrP plane were 
actively involved in covalent bonding the highest possible coverage due to the TEPI 
modifier would be 100/2 (bonded by both the amine group and the carbonyl group) 
which indicates an ideal surface coverage of 50%. Using SIMS we estimate the surface 
coverage for TEPI-ZrP is about 45.2% + 2.8%. Similarly for the DCMPS-ZrP material 
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there are two available Cl- groups which readily react with the available P-OH sites. The 
geometry and steric hindrance attributed to the methyl and phenyl groups the possible 
third occupation site is blocked effectively thus resulting in a tripod occupation. 
Additionally it is also possible to have Si-O-Si type bridging on the surface indicating 
only every other surface P-OH is modified successfully. While SIMS provides a pretty 
good estimation of surface coverage quality, the bonding information is insufficient for 
conclusive evidence.  In this case the ideal coverage would be about 33.33% and using 
SIMS surface coverage estimation the coverage is found to be 28.05%+2.3%. 
  
NMR Results Discussion 
TEPI / ZrP  
The 31P(1H) MAS NMR spectrum (Figure III-16) recorded at direct excitation 
shows the phosphorus pattern (-18.2, -20.2 and -21.6 ppm) typical of the ZrP matrix and 
a very low intense shoulder at -30.3 ppm, which can be well assigned to the surface 
phosphorus in the groups P-O-C(O)NH. In fact, the relative intensity of this line 
decreases in the 31P(1H) CP MAS NMR spectrum. In accordance with the structure, the 
13C (1H) CP MAS NMR spectrum of the compound exhibits six groups of resonances 
expected for the organic part: -1.5, 11.0, 21.6, 41.4, 61.4 and 156. 4 ppm (Figure III-17) 
assigned to CH2Si, CH3CH2, CH2-NH, CH2O and C(O)NH carbons. The appearance of 
the three resonances centered at 156.4 ppm can be explained by different local 
environments of the C(O)NH carbons on the matrix surface. 
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Finally, the proposed structure is supported by the 29Si (1H) CP MAS NMR 
spectrum where the group of the resonances at -56.2 - - 67.5 ppm is observed (Figure 
III-18).   
DCMPS / ZrP  
The 31P(1H) MAS NMR spectrum of this compound is very similar to that in 
Figure III-16 to show again the phosphorus ZrP matrix pattern and a very low intense 
shoulder at -29.7 ppm assigned to the surface phosphorus in the groups P-O-Si. Again 
the relative intensity of this shoulder reduces in the 31P(1H) CP MAS NMR spectrum  
supporting the assignment. Figure III-19 shows the 13C (1H) CP MAS NMR spectrum 
where the signals at -5.4 and 131.6 and 125. 9 ppm corresponds to the CH3Si(O2)C6H5 
structural units on the surface (the broad line is coming from the NMR probe). The two 
lines at 60.9 and 15.2 ppm belongs probably to ethanol located in the pores.  
The 29Si (1H) CP MAS NMR spectrum shows two sharp resonances at -28.2 and 
34.9 ppm (Figure III-20) again in accordance with the structure. 
LMA / ZrP  
The 31P(1H) MAS NMR spectrum of this compound shows the phosphorous ZrP 
matrix pattern and a very low intense shoulder located now at -23.1 ppm. The line can be 
assigned to the surface phosphorous in the groups P-O-CH2. The latter is supported by 
decreasing the relative intensity of the shoulder in the 31P(1H) CP MAS NMR spectrum. 
In spite of the very large number of scans, the signal/noise ratio in the 13C (1H) CP MAS 
NMR spectrum of this compound is poor (Figure III-21). 
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Nevertheless the resonances cantered at 62.3, 28.2 and 15.9 ppm can correspond 
to the aliphatic carbons in accordance with the expected structure. In addition, a very 
weal resonance at 166 ppm can belong to the carbonyl carbon R-O-C=O(CH)(CH2-O-
P)(CH3).  
 
Conclusion 
In conclusion, we have demonstrated the successful fabrication of surface 
modified α- ZrP crystals grafted with TEPI, DCMPS & LMA. Their chemical structures 
were confirmed via TGA, FTIR, solid state NMR and SIMS measurements. TEPI, 
DCMPS and LMA are powerful functionalization agents used to initiate the surface 
reaction of α-ZrP. We anticipate this introduces a new possible platform for further 
surface functionalization studies that may lead to a variety of applications. We also 
showed for the first time that SIMS in the event-by-event bombardment mode can be 
used to quantify the degree of surface modification in ZrP nanoplatelets SIMS also 
revealed possible surface polymerization for the LMA modified crystals and could 
potentially be applied in nano-composite quality determinations The established protocol 
could also quite easily translate to other inorganic materials such as TiO2 nano-sheets in 
determining the quality of surface coverage for nano-domain analysis. These reactions 
can delineate the path for useful new applications in building versatile and flexible 
“smart” platform for surface studies.       
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CHAPTER IV 
TOF-SIMS HOMOGENEITY CHARACTERIZATION OF 
INORGANIC LAYERED NANOMATERIALS (ILNs) IN DRUG 
DELIVERY SYSTEMS 
 
Introduction 
There is a general consensus the characterization of morphologies in the 
nanometric scale needs to be improved.16, 17 Intercalated nanomaterials pose the 
challenge of determining the effectiveness of intercalation, i.e. of characterizing 
materials that are likely heterogeneous. When considering nano sized materials there is 
the additional challenge arising from the complexity in accessing their physicochemical 
information in the nanometric domain. The intercalation chemistry of inorganic layered 
nanomaterials (ILN, such as metal phosphates and phosphonates, layered double 
hydroxides, clay materials, etc.) has been extensively studied.170  The practical 
applications of these materials are a subject of widespread study in today’s materials 
sciences and often require functionalization in order to improve their applicability.   
We selected a model inorganic layered nanomaterial, the theta phase of 
zirconium phosphate, Zr(O3POH)2·6H2O, referred to as θ-ZrP. The structure of α-ZrP 
has a layered configuration in which the Zr ions are slightly above and below the mean 
plane of the layer. Three of the monohydrogen phosphate oxygen atoms bond to three 
adjacent Zr ions with phosphate groups alternating above and below the plane. The 
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remaining OH groups form a bilayer in the interlamellar space (Figure IV-1a).  The 
theta phase has similar characteristics, except instead of only one molecule of water 
there are six in the theta phase. The ZrP particles are clay–like in that the 
hexacoordinated zirconium ions are sandwiched between outer layers of tetrahedral 
monohydrogen phosphate groups. ZrP has the ability to intercalate many species171-177 
and is also readily exfoliated.178 The surface consists of parallelogram arrays of P-OH 
groups as was shown by complete displacement of the hydroxide protons on the surface 
phosphate by Cs+ exchange.179 The surface area could be predicted by the size of the Cs+ 
ion and the number of protons liberated. These particles can be grown in sizes of less 
than 100 nm or as large crystals.180  
The ease of synthesis, of crystallinity and size control has allowed for α-ZrP to 
be used as the model system for intercalation chemistry studies for over four decades.148-
151 It represents an ideal platform for intercalation reactions. The immobilization of 
organo and metal-based modifiers on a variety of solid supports remains crucial for 
many applications. The studies presented in this article discuss ~150 nm ZrP NPs and 
subsequently explore the use of SIMS from a fundamental approach for the purposes of 
nanomaterial characterization. It has been shown previously how SIMS can be applied to 
intercalated structures.181, 182 The homogeneity parameter is of immense importance for 
the purposes of robust physicochemical characterization as it effects the bioavailability 
and hence the activity of the drug.  
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In designing a controlled-release drug delivery system, the matrix must be easy 
to manufacture,  be stable over an extended shelf life, and must deliver the appropriate 
drug dosage to the target area over the desired time period.89  Nano sized drug delivery 
carriers had shown the advantage of higher accumulation in tumor tissues via the 
enhanced permeation and retention (EPR) effect defined by leaky vasculature and poor 
lymphatic drainage commonly seen in solid tumors.183, 184 The superiority of ZrP 
materials over other ILN has been previously established: (1) not cytotoxic and not 
associated with any metabolic function;10, 185 (2) solved crystal structures;186, 187 (3) 
almost no impurities (<0.01%); (4) high ion exchange capacity of 6.64 meq. g-1 39  to 
accommodate higher loading of drugs; (5) stability under biological conditions; (6) 
chemically modifiable surfaces;150, 188 and (7) peculiar nano-platelet shape. The 
fabrication of drug delivery systems can be challenging due to the need for evaluation 
and analysis of the final product. One of the major advantages of these systems is their 
capacity to entrap high loads of bioactive species and protect their loads until they are 
released.158 With drug delivery systems using nano vectors gaining in popularity, vetting 
the efficacy and design of these systems becomes essential. There has been an increase 
in uptake and delivery systems that are ion exchangers such as metal phosphate materials 
(which are cation exchangers), layered double hydroxides (LDH) or hydrotalcites (which 
are anion exchangers), and clays mineral materials as smectites and laponites, among 
many others. Additionally polymeric drug hybrids have also gained a lot of popularity.       
Recently the potential of using layered structured nanomaterials (LSN) as non-
viral vectors and drug carriers has been explored. 5,11, 158, 189-191 In the last several years 
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nanoparticle-mediated drug delivery has been studied as a novel and valuable means for 
overcoming the problem of significant side effects (due to lack of specificity) and the 
emergence of drug resistance. The fabrication of controlled release systems can be 
technically difficult compared with conventional dosage forms, the evaluation and 
analysis of the final product is vital. While the Trojan horse concept of delivering the 
drug through stealthy means is an interesting approach, in reality how much of the drug 
is actually incorporated into the matrix. In addition the location of the drug in the context 
of overall assembly is of utmost importance for the long term success/failure 
evaluations. In practice, dissolution studies have the capability to monitor the rate of 
drug release; however, any unwanted effects observed by these methods cannot be 
readily associated with specific defects in the structure or composition of the controlled-
release system. An analytical technique is required that can probe the interior or probe 
cross sections of the assembly for the detection and distribution of various ingredients91. 
While it is important to recognize the benefits of molecular tagging an alternative 
method serving a parallel purpose may be developed utilizing the technique of SIMS. 
Traditionally polymeric drug delivery systems have been studied extensively using 
SIMS,93, 182, 192 however the use of ILNs for biomedical applications is a relatively new 
field with little to no literature showing the SIMS studies of these new materials.  In this 
paper we look at an ILN with a host of compatible anti-cancer drugs and evaluate their 
homogeneity side by side at various drug to substrate molar loading level ratios.  
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Experimental Methods 
 
Materials 
 Zirconium(IV) oxychloride octahydrate (ZrOCl2·8H2O), ethanol, acetone, cis-
diamminedichloroplatinum(II), molybdocene dichloride and doxorubicin were obtained 
from Sigma-Aldrich while the titanocene dichloride, 99% was purchased from Acros 
Organics and used without further purification. Phosphoric acid (H3PO4) at 85% (v/v) 
(ACS grade reagent) was obtained from Fisher. Water was of nanopure quality from a 
Zyzatech reverse osmosis water system (18 MW/cm). All glassware was cleaned with 
Alconox from VWR and rinsed with abundant nanopure water. For sample deposition in 
SIMS and CAMECA ion microprobe analysis, customized Si wafers with 200nm thick 
metal layer of Au was used. The silicon wafers used were P(100) 10-20 ohm/cm cut 
down to 7x7 mm using a diamond knife and purchased from Silicon Valley 
Microelectronics.   
 
Synthesis and Characterization 
 θ-ZrP was synthesized using a procedure reported by Kijima in 1982.22  The 
procedure consists of slow drop wise addition of 200 mL of 0.05M zirconyl chloride 
(ZrOCl2) solution to a preheated 200 mL solution of 6M H3PO4 at 94°C.The resulting 
solution is heated at 94°C for three days before the product is filtered and washed several 
times with water to obtain the θ-ZrP.  In a typical procedure the intercalation process 
was performed by the batch method, adding the desired quantity of the drug (cisplatin, 
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titanocene, doxorubicin or molybdocene) to a water suspension of θ-ZrP 
(Zr(O3POH)2·6H2O) with interlayer spacing of 10.3 Å) at different molar ratios (loading 
levels).The complete details of sample preparation can be found elsewhere.12a, 15 The 
complete characterization of the materials was performed using several analytical 
methods. The XRPD experiments were performed from 4° to 40° (2θ angle) using a D8 
X-ray diﬀractometer system (Bruker AXS, Madison, WI) with a copper anode source 
(Kα1, λ= 1.5418 Å) with a filtered flat LiF secondary beam monochromator for the 
ZrP:CisPt and ZrP:Dox samples. The divergence, receiver, and detector slit width was 2 
mm; the scatter slit width was 0.6 mm. The interlayer distances were determined using 
Bragg's Law for the (002) diﬀraction plane of the diﬀraction pattern of θ-ZrP and the 
(001) diffraction plane of the diffraction pattern for the intercalation products. For the 
ZrP: Cp2MoCl2 and ZrP: Cp2TiCl2 samples X-ray powder diffraction (XRPD) 
measurements were performed from 2 to 40° (in the 2θ axis) using a Siemens D5000 X-
ray diffractometer with Cu Kα radiation (λ = 1.5406 Å) with a filtered flat LiF secondary 
beam monochromator.  
The transmission electron micrographs (TEM) of the samples were acquired 
using a JEOL 2010 transmission electron microscope at an acceleration voltage of 200 
kV. Samples were prepared using copper grids from Ted Pella. X-ray elemental 
distribution “maps” were obtained at the Department of Geology and Geophysics at 
Texas A&M University. Quantitative compositional analyses were carried out on a four 
spectrometer Cameca SX50 electron microprobe. The detailed information is provided in 
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the SI.  The depth profile study was performed using the CAMECA IMS 4f ion 
microprobe employing a 5.5 keV oxygen plasma.  
 
SIMS 
The instrument used in these studies is a custom-built instrument equipped with a 
custom-built C60 source capable of producing C60
+,2+ at 26 & 43 keV total impact 
energy.130, 193 The instrumentation used for the analysis and the protocol used has been 
described extensively in the previous chapters.131  Briefly, the instrument is equipped 
with a 1m linear time-of-flight (ToF) and an electron emission microscope. The singly 
and doubly charged C60 ions of interest were mass selected using a Wien filter. The 
collection of the start signal is triggered by the emitted electron from the impacted site. 
The targets were interrogated using the C60 projectiles sent in one by one at a repetition 
rate of 1000 impacts/s. A single projectile impact stimulated emission of secondary ions 
from a surface area of ~10nm and depth of ~5nm.The mass spectrum from each 
individual impact was recorded in a discrete manner and resolved. There is no overlap in 
time or space between successive projectiles.194 This is key for effective quantitative 
observations in the event-by-event bombardment detection mode. The samples were 
negatively biased and each of the events was detected using an eight anode detector. The 
individual mass spectra were recorded and stored in a “total matrix of events” (TME)195 
and a summation of these individual spectra (~ 2 x 106 detection events) gives rise to the 
conventional mass spectrum. Using this technique it is possible to deconvolute the 
events with single secondary ion emissions and those with multiple emissions. If two or 
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more secondary ions are ejected from one bombardment event, they will be spatially 
related at the nanometric level.    Additionally, it is also possible to compute the yields 
for each of these ions and find associations in their coemissions.  Individual cluster 
impact TOF-SIMS consist of an accumulation of single events defined as one primary 
ion impact on target sample followed by the emissions of secondary ions and their 
subsequent detection. 
A coincidental ion mass spectrum is generated by selecting an ion of interest and 
recording the collection of all coemitted secondary ions under individual projectile 
impacts. The coincidence secondary ion spectrum contains the record of colocalized 
secondary ions emitted from a given nanovolume after each individual impact.196 Two or 
three discrete 200 μm radius spots were analyzed for each sample to ensure sample 
consistency and bulk homogeneity. 
 
Sample Preparation 
The Au coated Si wafers and stainless steel cubes were immersed and sonicated 
individually in ethanol and acetone baths for 10 minutes each. The wafers were then 
thoroughly dried with nitrogen. Each of the drug delivery ILN samples were agitated 
with DI water in 0.01% w/v using a sonicator for 15 min to create a slurry. 50 µL of the 
slurry was carefully drop-cast onto a cleaned wafer surface (Au side) and the moisture is 
allowed to dry quickly with the aid of a heating lamp. Once the material is affixed onto 
the wafer it is subsequently attached onto a stainless steel cube using carbon tape prior to 
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introduction into the vacuum chamber for SIMS analysis. For depth profile analysis the 
wafer is introduced directly into the vacuum chamber post deposition. 
 
Results and Discussion 
The objective of using SIMS in homogeneity analysis for nanomaterials utilized 
for drug delivery was both qualitative and quantitative.  The first was to recognize both 
substrate (ZrP) as well as drug specific (cisplatin, titanocene, doxorubicin or 
molybdocene) ions to ensure intercalation from a qualitative assessment point of view. 
Secondly, to recognize and access whether at the nanometric level these intercalations 
are too subtle or pronounced enough for quantification. To this effect the first study 
looks at the unique intergallery spaces of the substrate layered material which is 
combined with stoichiometrically different levels of anti-cancer therapeutics. A 
proposed schematic of the intercalation reaction is provided in Figure IV-2. Cisplatin 
(Pt(NH4)2Cl2/ MW 300.05 g/mol) was intercalated into θ-ZrP at stoichiometrically 
variant levels, to form three different materials with the ZrP:cisPt molar ratios varying 
from 1:1, 10:1 to 1:5 (Figure IV-3).  
Cisplatin-intercalated ZrP materials at different loading levels were synthesized 
with the purpose of elucidating how the modifications of the layered compound affect 
their structure, morphology, and physicochemical characteristics of the material, and 
study these characteristics in the produced materials. Figure IV-4 shows the XRPD 
patterns obtained for α-ZrP and θ-ZrP upon reaction with different ratios (loading levels) 
of ZrP:cisPt (θ-ZrP converts to the α phase upon drying and therefore the 
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characterization of the dried intercalation compounds is going to be compared with the α 
phase of ZrP).8 The XRPD patterns show the formation of a new phase with an 
interlayer distance of ca. 9.3 Å for all the intercalation products. In this new phase the 
interlayer distance of ZrP is increased by 2.7 Å, confirming that intercalation has taken 
place; α-ZrP has an interlayer distance of 7.6 Å but just one layer of ZrP has a thickness 
of 6.6 Å if the space occupied by the water molecule is excluded.197, 198 
Cisplatin within the ZrP matrix is separated both depth wise and via planarity due 
to the substrate’s layered nano structure.  The labile nature of the chloride ligands in the 
cisplatin complex makes highly likely that in the new phase the chloride ions are 
displaced by the phosphate groups from the layer (Figure IV-3).199 The location of the 
molecule facilitates the study of the secondary ion emission and its dependence on the 3-
D location of the molecule of interest. By observing the recombination fragments in the 
higher mass ranges due to the addition of the substrate group (PO2
- m/z 63) onto the 
identified cisplatin secondary ion Pt(NH3)2Cl
- (Figure IV-5) we were able to determine 
the successful intercalation.  
The negative ions in the mass range from m/z 320 to 340 are labeled as peaks 
suggested originating from the cisplatin addition to the ZrP, i.e., indicating the presence 
of the drug intercalation particulates (shown in Fig. IV-5 a&b).These are expected 
secondary ions considering the ion exchange capacity of ZrP.  Additionally it can be  
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seen that the intensity of the signal due to these secondary ions from the combination of 
the substrate with the intercalate increases with the increase in the amount of intercalate 
(drug) as is observed in the normalized mass spectrum from Figure IV-5b. This is 
further revealed by looking at the % yields of the secondary ions of interest. We observe 
that at the highest loading level of the drug the yields for the secondary ion attributed to 
the drug are consistent with those observed by the drug in its native state. Additionally 
we see the reduced yields of the secondary ions in question at the lower loading levels 
attributed to the layered assembly of the drug within the ZrP galleries. 
Because the location of the intercalate as well as the degree of distribution is of 
utmost importance for effective delivery, using the technique of SIMS the percent 
homogeneity of the material has been estimated. The impacts on the substrate (ZrP) were 
isolated from those on the intercalate (Pt(NH4)2Cl2). Additionally events that involved 
secondary ion emissions of both from the same emission volume were also estimated 
using coincidence mass spectrometry. Each of these event types is illustrated in Figure 
IV-6. This information was then compared to the total number of events. The 
homogeneity of the intercalation of the cisplatin into the interlayer galleries could thus 
be estimated by monitoring the compilation events or “event type 3”. A compilation 
event represents those events which result in the emission of secondary ions from both 
the substrate (ZrP) as well as the intercalate (cisplatin).  The distribution of the drug at 
stoichiometrically variant loading levels was calculated in a similar fashion. The degree 
of homogeneity of each drug-matrix nano composite was calculated using the  
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relationship described below. The ions that were used in each drug-substrate system to 
calculate distribution homogeneity are included in Table IV-1.  
The degree of homogeneity, expressed as a percentage can then be calculated and 
can be extracted from the experimental data using the following relationships: 
        
   
 = Nx                   %            
  
  
      
where, Ia,b  is the intensity of ion type a coemitted with ion type b, obtained from 
the coincidence emission spectra. Ia and Ib are the intensities of ion a and b respectively 
which are obtained from the cumulative total matrix of events spectra. Nx represents the 
number of effective impacts on the drug fragments in the presence of the substrate (ZrP) 
while No represents the total number of collisions. “Event type 3” leads to the 
homogeneity calculations using coincidence mass spectrometry.  
Using the afore mentioned setup the extent of homogeneity of the samples was 
estimated for each of the three ZrP:cisPt cases. The dimensions of each ZrP NP are 
approximately 150 nm with a thickness of about 15-30 nm depending on the size of the 
drug. Thus with each emission depth the chance of excavating a majority of the particle 
is quite high.  We find that the 1:1 sample where the ZrP and cisplatin are in equimolar 
concentrations reveals the highest level of mixing, with a 94% event compilation, 
followed by a 54% compilation for the 1:5 material where the cisplatin is 
heterogeneously distributed due to the agglomeration of the intercalate on the substrate 
surface due the drug being in excess. Since the depth of emission is ~10 nm the  
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accumulation of cisplatin on the surface of the ZrP NPs inhibits the detection of ZrP 
secondary ions. The least amount of event compilation of 24% is found in the 10:1 
where the substrate is in excess of the intercalate leaving behind several unsaturated 
galleries significantly reducing the probability of finding compilation events. This 
corroborates observations made with electron microprobe analysis. Figure IV-7 & 
Table IV-2 show the X-ray elemental distribution “mappings” obtained for the 10:1, 
1:1, and 1:5 intercalation products which show the atomic distribution of Pt, P, and Cl in 
a 62 x 62 μm2 section of the surface of the intercalation products. The X-ray elemental 
maps show uniform distribution of Pt and P in the 1:1 intercalation material with a very 
small amount of Cl. On the other hand for the 1:5 intercalation material there is an 
agglomeration of cisplatin on the surface with visible Cl depositions on the surface. In 
addition, for the 10:1 intercalation product there is a lack of Cl atoms, which was 
expected since in the intercalation product there appears to be a complete ion exchange 
of the drug into the ZrP layers.    
Additionally a depth profile study was performed using the drug delivery 
materials at the CAMECA 4f ion microprobe employing a 5.5 keV oxygen plasma beam 
to study the isotopic elemental signal due to 190Pt (intercalate) vs. the signal from 90Zr 
(from the substrate). The material was sampled at different points to check for 
consistency of the signal. The results were consistent with those found using the SIMS 
and microprobe analysis. From the 1:1 sample (Figure IV-8) it can be seen that over 
time, while the 90Zr signal is relatively constant for a singular spot (it fades once the 
entire sample has been excavated). 
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Figure IV-7:X-ray elemental distribution “maps “of ZrP:CisPt at 1:5, 1:1, 10:1 
molar ratios. The microprobe image composites X-ray maps were generated using 
the program Image J® by combining three 8-bit X-ray images into a false color 24-
bit RGB image, where red was selected for Pt, blue for P, and green for Cl. 
(Adapted from Reference 9) 
 
 
ZrP:CisPt MW O N P Cl Zr Pt 
(1:5) 437.623 33.52 1.70 14.57 1.29 20.79 12.74 
(1:1) 444.40 32.99 1.89 15.18 0 20.48 13.97 
(10:1) 311.51 48.19 0.36 21.70 0 29.21 0.78 
 
Table IV-2: Elemental analysis of ZrP:CisPt at 1:5, 1:1, 10:1 molar ratios for Pt, P, 
and Cl. (Reference 9) 
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(a) ZrP:CisPt 
(10:1) 
Point 1 
(cps)* 
Point 2 
(cps) 
Point 3 
(cps) 
Point 4 
(cps) 
Average 
(cps)* 
190 Pt 15000 2971 3555 3373 3300 
90Zr 227000 87300 83000 364000 178100 
 
 
(b) 
ZrP:CisPt(1:1) 
Point 1 (cps) Point 2 (cps) 
Point 3 
(cps) 
Average (cps) 
190Pt 30400 33800 34700 32967 
90Zr 189000 215000 198000 200667 
 Table IV-3. Depth profile study results obtained using the CAMECA 4f using a 5.5keV 
O2
+ beam for ZrP:CisPt in (a) 10:1 (b) 1:1 loading ratios. (* Point 1 has been excluded 
after performing Dixon’s Q test. The heterogeneity is an expected feature of this 
material since the substrate is in considerable excess of the intercalate. ) 
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The signal from 190Pt steadily decreases hinting at the layered arrangement. Furthermore, 
it can be seen that there is a signal correlation in the 10:1 sample when compared to the 
1:1 sample (Table IV-2). The 90Zr/190Pt ratio for the signal of the (10:1) sample reveals a 
proportion of ~54 while the same ratio for the (1:1) sample reveals a proportion of ~ 6. 
The signal ratios for the (10:1) sample/ (1:1) sample result in a proportion of ~9 which is 
in close agreement with the expected value of 10 for the excess ZrP present in the former 
sample as compared to the latter (Table IV-3).   There appears to be a direct relationship 
between the intensity of the signal measured in counts per sec (cps) for each of the 
isotopes in the corresponding materials that is further elucidated using depth profile 
analysis.  
The 1:1 combination of the drug: substrate was analyzed for the next set of drugs, 
i.e., doxorubicin, molybdocene and titanocene. Figure IV-9 shows the XRPD pattern 
obtained for the intercalation product of doxorubicin into θ-ZrP. For the ZrP:Dox 
reaction product the resultant d001 plane shifts from 10.3Å in θ-ZrP to 20.3Å confirming 
the intercalation of doxorubicin. Figure IV-10 shows the X-ray diffractograms for α-ZrP, 
θ-ZrP and the intercalation products for the reaction of ZrP and molybdocene dichloride. 
The appearance of a new phase at 10.8 Å is attributed to the resultant ZrP: Cp2MoCl2 
complex. Figure IV-11 shows the XRPD for α-ZrP, θ-ZrP and compared to the 
intercalation products of the reaction of ZrP and titanocene at several titanocene:ZrP 
molar ratios. Only the highlighted XRPD material is for consideration in the course of 
this thesis. The d001 plane is at 9.8 Å in the resultant ZrP: Cp2TiCl2 material.     
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 For each of the drug:ZrP samples, the combinant secondary ions attributed to the ion 
exchange reaction between the drug and the substrate were identified and have been 
elucidated on each individual mass spectra. Next the % homogeneities for each were 
also determined. Figure IV-12, 13 & 14 determine the cumulative mass spectra for 
ZrP:doxorubicin, ZrP:titanocene and ZrP:molybdocene respectively. A sample 
calculation is illustrated in the case of doxorubicin (C27H29NO11 /MW 543.52 g/mol) in 
Table IV-4. The Neff/No for ZrP is equal to that of doxorubicin indicating that the 
effective number of impacts on the drug are equal to those on the substrate thus 
revealing the homogeneous nature of the drug-substrate assembly. Additionally the % 
homogeneity is calculated to be 90% using the earlier given relationship. The mass 
spectrum in Figure IV-10 shows a signature fragmentation pattern elucidated by the subsequent 
N15 additions in the higher mass regions between m/z 280–350 attributed to the drug also 
appearing in the drug:substrate hybrid material albeit in smaller yields due to the layers of ZrP 
that it is incorporated in.       
The next sample that was analyzed for homogeneity was titanocene (Cp2TiCl2/ 
MW 248.96 g/mol) intercalated in ZrP, (Figure IV-13). The information from the 
impacts on the substrate (ZrP) were isolated from those on the intercalate Cp2TiCl2. 
Additionally events that involved secondary ion emissions of both from the same 
emission volume were also estimated using coincidence mass spectrometry. This 
information was then compared to the total number of events (>1 million). The 
homogeneity of the intercalation of the titanocene into the interlayer galleries could 
thusly be estimated by monitoring the compilation events. The % homogeneity for the  
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[Figure IV-10: Negative ion mass spectra of doxorubicin intercalated in ZrP 
nanoplatelets at 1:1 loading level vs. doxorubicin.  The spectra are obtained under 
C60
2+ bombardment at 43 keV total impact energy. The peak intensities are 
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titanocene dichloride intercalated ZrP at the 1:1 loading level was calculated to be 91%. 
The secondary ions from the intercalate are marked in the mass spectrum. The 
homogeneity of molybdocene dichloride (Cp2Cl2Mo/ MW 297.04 g/mol) intercalated 
ZrP at the 1:1 loading level was also estimated in a similar fashion and found to be 
~91%. In Figure IV-14 the clustering effect of the secondary ions is observed due to the 
presence of the seven stable isotopes (masses 92, 94, 95, 96, 97, 98, and 100) of 
molybdenum leading to the appearance of sequential clusters.  
In order to facilitate the identification of additional secondary ions a coincidence 
spectrum was obtained (Figure IV-14b) by putting a window onto the m/z 63, PO2
- 
.This simplified the spectra while making apparent the secondary ions that can be 
attributed to the intercalated material. In the case of 150 nm intercalated ZrP NPs the 1:1 
drug to substrate loading ratios seem to provide the best level of homogeneity in each of 
the four separate drug delivery systems that were tested and hypothesized. Table IV-5 
provides a quick recap of all the homogeneity results that were obtained. It would be 
interesting to test this theory out with other types of ILNs more extensively in the future.   
 
Conclusions 
This study illustrates the ability of SIMS in the individual impact mode to a) 
provide a label-free mass spectrometric technique for the qualitative assessment of drug 
intercalated ILNs as has been illustrated by the incorporation of four distinct drug 
molecules into the ZrP substrate b) quantify the degree of homogeneity and distribution 
of the drug within the confines of the substrate as was illustrated specifically with the 
126 
 
ZrP:cisPt intercalation reactions in the nanometric domain through standardized sample 
preparations. Each of the studies presented demonstrates the ability of SIMS in the mode 
of single cluster impacts to determine composition and homogeneity with ∼20 nm 
spatial resolution127. The scope of the type of applications and materials discussed in this 
model system study are quite extensive and may be broadly applied as a possible tool for 
nanomaterial characterization in drug delivery material characterization. 
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CHAPTER V 
CONTROLLED RELEASE OF ANTICANCER DRUG 
ENCAPSULATED INORGANIC LATTICE TO GOVERN DRUG 
UPTAKE MECHANISMS* 
 
Introduction  
This chapter demonstrates, the very small, but growing body of literature 
regarding a recently discovered application of layered compounds, which involves the 
ability of layered materials to sequester and later release molecules of chemical and 
biological significance. The use of cytotoxic drugs in chemotherapy is a widely 
prescribed method of cancer treatment. The side effects of using anticancer drugs to 
tumor cells are well documented and hard to circumvent. In recent years nanoparticle 
mediated drug delivery for overcoming the damaging effects of these drugs is an 
emerging strategy. For successful cancer therapy, high efficacy and low side effect drugs 
are highly needed, which might possibly be achieved by drug-nanoparticle hybrid 
systems. A relatively new addition in the realm of nanoparticle mediated drug delivery is 
the use of inorganic layered nanoparticles.8, 11, 50, 157  
 
 
 
 
 
*Parts of this chapter are reprinted with permission from Nanoscale, Volume 5, Agustín Díaz,   
Millie L. González,   Riviam J. Pérez,   Amanda David,   Atashi Mukherjee,   Adriana Báez,   
Abraham Clearfield and Jorge L. Colón, Direct intercalation of cisplatin into zirconium phosphate 
nanoplatelets for potential cancer nanotherapy, pages 11456-11463, 2013. Copyright [2013] Royal 
Society of Chemistry. 
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They afford greater robustness in structural determination as well as significant  
characteristic information about drug loading and homogeneity as was described in the 
previous chapters. Several previous studies with similar materials have suggested that 
anticancer drug loaded inorganic layer nanoparticle systems offer considerable enhanced 
cellular uptake of drugs and consequently suppress cancer cell proliferation effectively 
as well.200-202  
 In literature the use of luminescent porous silicon oxide nanoparticles,203 gold (or 
silver) nanoparticles204 have emerged as among the most successful inorganic based 
nanoparticles. They, however have shown evidence of cellular cytotoxicity and 
hemolytic activity.205, 206 In addition as discussed in the introduction of this thesis, the 
spherical shaped nanoparticles exhibit poor penetration through vascular fenestrations 
and diminished endothelial wall adherence. The use of non-spherical, size controlled 
layered nanomaterials can lend itself to enhanced permeability and retention (EPR) by 
which macromolecules can accumulate passively and preferentially. The carrier material 
encapsulates and protects the drug from external media. This ensures the drug remains 
biologically inactive until a “trigger” enables the drug-loaded material inside the cancer 
cell where the cargo may finally be selectively released. This “trigger” is the dissolution 
of the carrier material in the micro-acidic cancer cell or cell lysosomal environment. The 
delamination or direct ion-exchange of the intercalated drugs with the ions in the cell 
interior allows for the eventual release of the drug.73    
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 In this present study, anticancer drug intercalated zirconium phosphate 
composites are investigated for their drug release profiles and capacities as a function of 
the drug loading and material homogeneities. Additionally, this chapter attempts to 
investigate the cellular interaction and uptake of nanoparticles since ZrP is being 
considered as a possible candidate for drug delivery nano vehicles. Since ZrP is 
relatively harmless to the body and is not associated with any metabolic functions it 
makes for an ideal candidate. The platelet-like shape of these materials shows better 
adhesion, margination and binding properties than its spherical counter parts.74, 75 While 
under standard biological conditions (pH – 7.2 – 7.4) ZrP is relatively stable, it is 
expected that once it reaches a low pH environment such a cancerous cell 
microenvironment where the pH is generally low (pH 4), it will release its loaded drug 
cargo. In addition, as the drug-loaded ZrP nanoparticles reach the extreme conditions of 
the lysosome and the peroxisomes, they will dissociate the ZrP to form phosphate ions 
and harmless zirconium salt or oxide both of which have excellent renal clearance.8  
Designing nanomedicines with enhanced and intentional functionalities requires an 
understanding of the intracellular trafficking pathway of nanoparticles so that their fate 
in the cell can be predicted. In the literature it has been reported that nanoparticles such 
as iron oxide and silica, as well as carbon nanotubes are internalized in cells via 
endocytotic pathways.201, 207-209 Endocytosis is a conserved process in eukaryotes by 
which extracellular components are taken up into cells by invagination of the plasma 
membrane to form vesicles that enclose these materials.  
  
 131 
 
 This chapter discusses specifically the effectiveness of the ZrP nanoparticles in 
the delivery of cisplatin and doxorubicin drugs. The cisplatin and doxorubicin 
intercalated ZrP nanoplatelets were explored for their cytotoxicity elsewhere.158 In brief, 
the toxicity of ZrP nanoparticles has been extensively explored from normal to 
malignant human cells (Figure V-1&2). The biocompatibility of the ZrP NPs were 
assessed using an MTT assay, a colorimetric assay for assessing cell viability in different 
cells lines. The human embryonic kidney cells lines or the HEK-293 are commonly used 
in drug toxicity studies to assess effects of drug candidates on the renal system. ZrP NPs 
at concentration of upto 1000 μg mL-1 don’t appear to affect the cell viability of the 
HEK-293 after 24 h and 72 h incubation times indicating the benign nature of ZrP to 
human kidneys (Figure V-1). The ZrP nanoplatelets are also found to be nontoxic to the 
human metastatic breast cancer (MDA-MB-231) cell lines after 24 h, 48 h and almost 96 
hrs. of incubation (Figure V-2). This indicates that the ZrP alone does not have any 
cytotoxic effects on the cells and can be used as a vehicle for drug delivery. 
Additionally, it has also been demonstrated that ZrP NPs are highly hemocompatible, 
showing no hemolytic activity towards the human red blood cells (RBCs).158  
In this study, the in vitro release profiles of doxorubicin loaded ZrP and cisplatin 
loaded ZrP were investigated. In the case of the anticancer drug Cisplatin (cis- 
diamminedichloroplatinum(II), cis-Pt(NH3)2Cl2), the platinum complex is monitored in 
the release studies from the nanoparticles and the particle degradation in simulated body 
fluid (SBF) and artificial lysosomal fluid (ALF). 
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Doxorubicin being confocally active was monitored using fluorescence microscopy to 
quantify release in a similar fashion. Subsequently the delamination of the ZrP material 
is also monitored using elemental zirconium quantification over time. Next the cellular 
uptake mechanisms employed in nanoparticle uptake were also explored using HeLa 
cells lines.  
  
Experimental Methods    
 
Materials  
Zirconium(IV) oxychloride octahydrate (ZrOCl2·8H2O), ethanol, acetone, cis-
diamminedichloroplatinum(II) and doxorubicin hydrochloride were obtained from 
Sigma-Aldrich (St. Louis, MO).  Phosphoric acid (H3PO4) at 85% (v/v) (ACS grade 
reagent) was obtained from Fisher. Water was of nanopure quality from a Zyratech 
reverse osmosis water system (18 MW/cm). Other chemicals and reagents were of 
analytical grade. 
 
Intercalation Procedure 
 The intercalation procedure has been described in the previous chapters. In brief, 
the intercalation was performed by the batch method by adding 50 mL of a solution 
containing θ-ZrP with the desired quantity of cisplatin or doxorubicin. The loading 
levels used in the course of this study for the cisplatin loaded drugs were: 1:1 , 1:5 and 
1:10 cisplatin:ZrP. For the doxorubicin intercalations doxorubicin at different 
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concentrations (0.14, 0.25 and 0.35 ratio of DOX to ZrP (DOX:ZrP) w/w) for five days 
to produce varied loading levels in the desired materials. The intercalation was done in a 
dark environment at room temperature; monitoring the intercalation procedure by the 
change in pH in the case of both drugs. When the pH finally stabilized (approximately 5 
days later) the suspensions of each material were centrifuged and subsequently filtered 
using a 0.22 μm Millipore filter membrane.  
At this stage the filtered material was divided up into two parts for each of the 
above samples. The first half was re-suspended in ~50 mL of miliQ water while the 
second half was dried under vacuum and subsequently pulverized. The powdered 
material was used for the purposes of characterization while the second part was used for 
the purposes of cell work and release studies.  In terms of the doxorubicin release studies 
only the 14% and 25 % loading levels (w/w) were concentrated upon to establish the 
difference in drug release behavior. The highest loading level 1:1 or 35% loading by 
weight was used for the purposes of the cell mechanism study.   
 
Instrumentation  
 Most of the characterization for the dried materials were described in detail in the 
previous chapters. Briefly, some of the techniques are discussed:  
 
X-ray Powder Diffraction Analysis (XRPD)  
These experiments were performed using a D8 X-ray diffractometer system 
(Bruker AXS, Madison, WI) with a copper anode source (Kα,λ = 1.54Å) equipped with a 
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flat filtered LiF secondary beam monochromator. The divergence receiver and detector 
silts are all 2mm apart and the scatter slit width is 0.6 mm. The interlayer distances are 
determined using the Bragg’s law for the (002) diffraction plane of the θ-ZrP. The 
intercalations for each material are compared to the θ-ZrP and α-ZrP to establish a 
successful reaction. 
 
Transmission Electron Micrography (TEM) 
The transmission electron micrographs (TEM) of the samples were acquired 
using a JEOL 2010 transmission electron microscope at an acceleration voltage of 200 
kV. Samples were prepared by dispersing the solids in ethanol with an ultrasonic bath 
followed by deposition on a formvar/carbon coated copper grid (Ted Pella, Inc., 
Redding, CA).     
 
Microprobe Analysis 
Quantitative compositional analyses were carried out on a four spectrometer 
Cameca SX50 electron microprobe in the Department of Geology and Geophysics at 
Texas A&M University.  Analyses were run at an accelerating voltage of 15 kV at a 
beam current of 20 nA. All quantitative work employed wavelength-dispersive 
spectrometers (WDS).  Analyses were carried out after standardization using very well 
characterized compounds or pure elements. Qualitative analyses (spectra) were obtained 
with an Imix Princeton Gamma Tech (PGT) energy dispersive system (EDS) using a 
thin-window detector. 
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Typical accuracy for major elements (> 10 wt. %) is about =+/- 1 to 2 % of the 
amount present; the uncertainty at low concentrations would increase as the 
concentration decreased, with the uncertainty reaching 100% at the lower limit of 
detection (LLD).  The lower limit of detection for most elements under typical 
conditions would usually be about 0.05 to 0.10 wt. %.  Pressed powder samples will 
have some additional uncertainty based on surface roughness.  The main effect of 
surface roughness will be to reduce analytical totals because of X-ray scatter.  However, 
X-ray scatter is also wavelength dependent, which could result in a few percent change 
in apparent elemental ratios if the surface is very rough and there are significant 
differences in wavelength. 
 X-ray elemental distribution “maps” were obtained at 15 kV and 20 nA. beam 
current in beam scanning mode. For the 1500x (62 µm) maps, the beam was rastered in a 
256 by 256 point grid, with a grid spacing of 0.24 microns and a total acquisition time of 
600 seconds. Composite X-ray maps are generated by combining three 8-bit X-ray 
images into a false color 24-bit RGB image (ImageJ program) 
 
Dynamic Light Scattering (DLS) 
 The particle size and zeta potential of the ZrP nanoplatelets were determined 
using a Brookhaven ZetaPALS particle and zeta potential analyzer (Holtsville, NY).   
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Inductively Coupled Plasma-mass Spectrometry (ICP-MS) 
The ICP-MS analyses were performed on a Perkin Elmer NexIon 300 D 
instrument running in the standard mode with a quadrupole mass spectrometer (1% nitric 
acid matrix was used to digest the samples). 
 
Microscopy 
 Imaging was performed on an inverted epiﬂuorescence microscope (Model 
IX81; Olympus, Center Valley, PA). Images were captured with a Rolera-MGI Plus 
back-illuminated EMCCD camera (Qimaging, Surrey, BC, Canada). Imaging was 
performed using bright-ﬁeld and ﬂuorescence imaging with the RFP ﬁlter set (Ex = 560 
+ 20 nm/Em = 630 + 35 nm). The excitation light was from a 100 W mercury lamp 
(Leeds Precision Instruments # L202 Osram) passed through the ﬁlter cubes and a 100X 
objective. The bright-ﬁeld and ﬂuoresce images were captured with the Slide Book 4.2 
software (Olympus). 
 
In vitro Drug Release Study 
The in vitro drug release profile experiment was performed using the dialysis 
method. The simulated body ﬂuid (SBF) was prepared according to Kokubo and 
Takadama.210 Brieﬂy, NaCl, NaHCO3, KCl, K2HPO4·H2O, MgCl2·6H2O, CaCl2·2H2O, 
and Na2SO4 salts were dissolved in mili Q water and buffered with TRIS (99% Aldrich) 
and HCl in order to keep pH at 7.4 at 37ºC. Each salt was allowed to dissolve fully prior 
to the next salt addition. In addition the containers used were cleaned thoroughly with 
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dilute HCl to ensure no contamination occurred. Artificial lysosomal fluid (ALF) was 
used to simulate different interstitial conditions in the cellular environment that the 
nanoparticles may encounter after phagocytosis which is for all essential purposes the 
cell’s “feeding” mechanism. It was prepared by dissolving MgCl2, NaCl, Na2HPO4 , 
Na2SO4, CaCl2.2H2O, sodium citrate, C6H8O7, NaOH, glycine, sodium tartrate 
dehydrate, sodium lactate and sodium pyruvate in miliQ water. 211   
In a typical experiment a suspension of about 0.00067% w/v (g/mL) of the 
intercalated material (cisPt@ZrP) was exposed with SBF (pH = 7.4) or ALF (pH = 4.5), 
simulating the same ionic concentration of human environment. The suspension of the 
intercalated material was agitated using polypropylene vials and placed into an orbital 
shaker (VWR International, LLC, Suwanee, GA) at 37 ºC and 130 rpm. Aliquots of 5 μL 
were taken at specified periods of time from the external volume. The aliquots were 
centrifuged for a period of 1 minute to avoid any possible light scatter. The release of the 
platinum complex from the layers was monitored by ICP-MS, by determining the Pt 
concentration in each aliquot. At the same time the concentration of Zr was also 
monitored by ICP-MS to determine the hydrolysis of the nanoparticles under biological 
conditions. The release tests were repeated thrice for establishing consistency. 
The in vitro release behaviors of DOX from DOX:ZrP NPs were also monitored 
using simulated body fluid (SBF) (pH 7.4) or ALF (pH 4.5). Briefly, ~10 mg of 
DOX:ZrP NPs at various loading levels were immersed individually in 45 mL of SBF or 
ALF and sampled at predetermined time intervals. The concentration of DOX in the 
sample was measured using a DU 800 UV-vis spectrophotometer (Beckman Coulter, 
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Inc., CA) at a maximum absorbance of 488 nm after centrifugation. The release profile 
was obtained by plotting the cumulative release (%) against time:  
Cumulative Release (%) = [Pt]t / [Pt]o X 100 
[DOX]t / [DOX]o X 100 
[Zr]t/[Zr]o X 100 
where [Pt]t , [DOX]t and [Zr]t are the concentrations of Pt, Doxorubicin and Zr, 
respectively, at time t and [Pt]o, [DOX]o and [Zr]o are the total amount of Pt, 
Doxorubicin and Zr used in the experiment, respectively. Quantitative determinations of 
DOX were based on pre-calibration of the spectrometer using standard solutions of DOX 
in both SBF and ALF. The DOX release test was performed in the darkness. The release 
tests were repeated 3 times (three independent experiments) and the results are given as 
average values and standard deviations. 
 
Immunofluorescence/Confocal Microscopy  
HeLa cells were seeded on 12-well slides (5 X 103 cells/well) and incubated with 
10 μg ml-1 ,chlorpromazine (CPZ), 1 μg ml-1 filipin, or 100 μM amiloride hydrochloride 
for 1 hr at 37 ºC to examine the effects of a membrane entry inhibitors. This was 
followed by incubation with 10 μg/mL of 35% w/w DOX-ZrP for 2h. Chlorpromazine, 
filipin, and amiloride were used to inhibit the clathrin-mediated endocytosis, caveolae-
mediated, and macropinocytosis mediated endocytosis respectively. The cells were 
washed twice with PBS, harvested by scraping, suspended in lysis buffer, and then the 
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intracellular doxorubicin content was analyzed by fluorescence microscopy. Image 
acquisition and analysis was done using the Image J® program.  
 
Results and Discussion  
The ZrP nanoparticles were characterized using XRPD and TEM to reveal the 
successful intercalation of each of the drugs. The hexagonal, thin platelet-like shape with 
homogenous size distribution was monitored in each case. The X-ray diffractograms 
were discussed in detail in the previous chapter.  In the case of the cisplatin intercalated 
materials the x-ray diffractograms show the formation of a new phase with an interlayer 
distance of ca. 9.3 Å at all loading levels. The d002 plane for the cisplatin intercalated 
material at 9.3 Å interlayer distance indicates the molecules are oriented with their 
square planar molecular plane inclined at 45˚ with respect to the ZrP plane.8 The 
chloride ligand substitution by phosphate groups of the ZrP layers was further confirmed 
by microprobe and ICP-MS quantitative compositional analyses. Table V-1 shows the 
results of microprobe and ICP-MS quantitative compositional analyses of the 
intercalation products at all loading levels. The chemical composition of the intercalation 
products indicates that the chloride concentration in the intercalation products is 
substantially lower than pristine cisplatin. Figure V-3 shows the X-ray elemental 
distribution “mappings” obtained for the 1:1 vs. 5:1 intercalation products.  The atomic 
distribution of Pt, P, and Cl in a 62 x 62 μm2 section of the surface of the intercalation 
products reveals a marked difference in the Cl concentrations observed. This is further 
corroborated by the ICP-MS and microprobe results.  
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The intercalation of doxorubicin into θ-ZrP was carried out by direct ion-
exchange (Scheme 1).The X-ray diffractogram peaks for the DOX loaded ZrP exhibits 
an interlayer spacing at 20.3Å. This indicates π-π interactions between the DOX 
molecules and the protonated amine groups between the DOX and the deprotonated 
phosphate groups of the layers.158 This plays a crucial role in the packing arrangement 
within the layers. In the case of the lower loading levels (14% or 25%) it should be noted 
that there is a mixture of phases, where the peak corresponding to the alpha phase is still 
present. Fig. V-4 shows scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM) images of the DOX:ZrP intercalation product. The images show the 
characteristic platelet like hexagonal shape of the ZrP nanoparticles. The average 
particle size of DOX:ZrP nano-platelets is ~150 nm in diameter. The thickness of the 
particles increased from ca. 12 nm to ca. 32 nm due to the interlayer expansion post 
intercalation. 
 
In Vitro Drug Release 
 Drug efficacy of the CisPt:ZrP and DOX:ZrP nanohybrids is strongly associated 
with the intracellular concentration of CisPt and DOX delivered by ZrP nanocarriers. 
The in vitro release experiments of DOX from DOX:ZrP nanoparticles and CisPt from 
CisPt:ZrP nanoparticles were investigated by the dialysis method with SBF (pH 7.4) and 
ALF (4.5) as a release medium. The SBF had the same ionic concentration of human 
plasma and ALF has the same ionic concentration as a lysosomal microenvironment. 210, 
212 A brief animation scheme of the experimental design is illustrated in Figure V-5.  
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As shown in Fig. V-6, the release of DOX in the first day is roughly about 40% 
from both 14% and 25% loaded DOX:ZrP nanoparticles in SBF.158 It is interesting to 
note that the release of Zr in the SBF environment for all loading levels of DOX:ZrP is 
negligible and hence a graph for the same has not been included. However in the ALF 
environment 43% of the DOX was released for the 14% loaded DOX:ZrP material and 
15% of the DOX is release for the 25% loaded DOX:ZrP (Figure V-7). Simultaneously 
in the ALF environment at the 24 hour mark about 20% of the Zr for the 25% LDL 
DOX:ZrP and 25% of the Zr in the 14% LDL DOX:ZrP was released indicating the 
breakdown of the matrix allowing for the DOX to escape. Over a 10 day experiment 
period roughly a little under 40% of the ZrP matrix broke down to release the drug in the 
ALF environment. The drug however, goes through slow release and it took almost 
another 10 days to get to an 88% release from the 14% and it took about 14 days for the 
release of 80% DOX 25% loaded material. A slow release mechanism ensures the 
sustained DOX release for two weeks. Looking at the simultaneous Zr release shows that 
the delamination of the ZrP is a possible reason for the slow release mechanistically of 
the DOX. Additionally, ion exchange and drug diffusion may also be responsible. The 
delamination and break down of the ZrP material makes it an ideal drug delivery matrix. 
This will enable efficient renal clearance and drug dissemination. Interestingly, the 35% 
w/w loaded DOX:ZrP showed little to no release in both SBF and ALF (hence not 
shown in graphs). We hypothesize the tight packing of the DOX within the ZrP layers 
doesn’t allow the solvent diffusion and the slow Zr break down prevents the release of 
the drug. 
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With respect to the DOX:ZrP homogeneity from the previous studies it was established 
that the 1:1 or 35% w/w material is the most homogenous with a 91% surface 
homogeneity. We hypothesize that overly homogenous and tightly packed nanoparticles 
don’t afford the best drug release and thus may not be the ideal loading level for the 
most efficient drug dissemination. This is an important discovery relating to the nature 
of drug-nanoparticle hybrids. Additionally, it is clear that the ZrP matrix preferentially 
breaks down in the lower pH ALF environment vs the SBF environment. The overall 
DOX release in SBF is quite comparable with that of the ALF indicating that diffusion 
or ion exchange over material degradation and subsequent release drives the DOX-ZrP 
release mechanism.    
For the cisplatin loaded ZrP the release was monitored via ICP-MS by observing 
the platinum (Pt195) and (Zr91) signals over time (Figure V-8). At pH = 7.4 under the 
SBF condition the Pt release takes place within the first 12 h. It is only between 2% to 
3% of the theoretical maximum. The release profile reaches a plateau after the first 12 h 
that is maintained for several days. The Pt released under these conditions is assigned to 
the accessible platinum on the surface and edges of the ZrP nanoparticles, not from the 
Pt intercalated complexes within the ZrP layers. The slow release of cisplatin at pH = 7.4 
under SBF conditions is highly desirable in order to avoid the general administration of 
the drug and the many side effects related to this phenomena.  On the other hand, rapid 
release of the Pt complex from the ZrP galleries at low pH is desirable since it 
approaches the typical pH of the acidic environment of the tumor endosomes, and 
lysosomes which was discussed in detail previously.213, 214 
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The release profile of the platinum complex from the ZrP nanoparticles under the pH = 
4.5 ALF condition shows a much faster release, compared to the release in SBF (pH = 
7.4), with almost 50% of release after the first 12 hours for the 1:5 molar ratio. The 
release is faster for the 1:5 molar ratio sample than for the 1:10 and the 1:1 molar ratios 
samples. This difference can be explained by taking into account the structure of the 
cisPt@ZrP nanoparticles for each molar ratio. Furthermore, as previously discussed the 
material homogeneity for the 1:5 sample is ~54% in comparison with the 1:1 sample 
which has a much higher sample homogeneity ~94%. The empty galleries for the 1:5 
sample allows for much easier solution diffusion in comparison with the 1:1 loaded 
samples.     
The 1:1 molar ratio sample is a fully loaded material, where most of the platinum 
complexes are covalently bonded to the layers in a cross linked fashion, making the 
protonation of the phosphate to release the Pt complex and ligand exchange of the 
platinum complex more difficult due to the steric hindrance of the system. In the case of 
the cisPt@ZrP 1:10 molar ratio sample, the platinum complex is less hindered, but is 
more diluted throughout the whole nanoparticle, making the release slower. In the case 
of the cisPt@ZrP 1:5 molar ratio sample there is a higher concentration of the Pt 
complex than the 1:10 molar ratio sample but less hindrance than in the 1:1 molar ratio 
sample because the system has not reached saturation, producing a faster release. The 
hydrolysis of the Zr atoms from the ZrP layers was also monitored while the release of 
Pt takes place in the ALF. The release of Zr atoms into the medium is indicative of 
hydrolysis of the particles, which is important for the clearance of the inorganic 
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nanoparticles from the body. The hydrolysis of the nanoparticles produced a soluble Zr 
salt and inorganic phosphate that can be reused in the biological system. Figure V-8B 
shows the release of Zr atoms with time. The release of the Zr is slower in comparison to 
the release of the Pt from the particle, which implies that the hydrolysis of the platinum 
complex is faster than to the hydrolysis of the nanoparticles under lysosomal conditions.         
The reason for the difference in release profiles for DOX loaded ZrP vs CisPt 
loaded ZrP can be attributed to the fundamental differences in their intercalation 
mechanism. While DOX is sequestered in ZrP through direct ion exchange the 
intercalation mechanism for cisplatin is based on the covalent bonding of cisplatin. The 
chloride ligand substitution by phosphate groups of the ZrP layers allows for a more 
stable structure and better bonding.    
Recent studies show that burst release profiles of drug-loaded polymeric 
nanoparticles and liposomes are undesirable due to increased local and systemic toxicity, 
low drug availability at the tumor site, and consequently a reduced therapeutic effect.215 
Therefore, the slow release profile of cisPt@ZrP may be pharmacologically 
advantageous by increasing the time of exposure of the tumor cells to the drug. Due to 
the enhanced permeability and retention effect (EPR) when using ZrP nanoplatelets as 
carriers, cisplatin will be released mainly into the tumor cells which could result in lower 
systemic toxicity to the patient. 
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Uptake Mechanism  
Drug efficacy of the DOX-ZrP nanohybrid is strongly associated with the 
intracellular concentration of DOX delivered by ZrP nanocarriers. To further investigate 
the possible mechanism responsible for the DOX-ZrP uptake, the uptake modulation 
after the inhibition of different endocytic pathways was evaluated. There are several 
possible endocytic pathways for internalizing ZrP nanoparticles, such as clathrin-
mediated endocytosis, caveolae-mediated endocytosis, and macropinocytosis-mediated 
endocytosis (Figure V-9).216 We determined the specific endocytic pathway used by the 
ZrP nanoparticles for membrane entry by confocal microscopic studies. Since 
doxorubicin is fluorescent, this particular aspect of the study focuses solely on DOX-ZrP 
nanoparticles.   
HeLa cells were pre-incubated with endocytosis inhibitors for 1 h at 37 ºC 
followed by treatment with DOX and 35% LDL DOX-ZrP at 10μM concentration for 
the sake of simplicity for 2 h. The particle sizes of ZrP and DOX:ZrP were measured by 
transmission electron microscopy (TEM) and dynamic light scattering method. The 
samples used were constantly agitated to avoid agglomeration. Endocytosis pathways are 
subdivided into categories based on the size of the molecules being internalized. 
Chlorpromazine, filipin, and amiloride were used to inhibit the clathrin-mediated 
endocytosis, caveolae-mediated one, and macropinocytosis, respectively. The amount of 
intracellular DOX was captured using confocal microscopy and Image J to quantify the 
images captured. As shown in Fig. V-10, the uptake amount of DOX was modulated by 
shutting down each endocytotic pathway one by one to narrow down which mechanism 
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is the most actively involved. For the clathrin mediated endocytosis the portals for the 
endocytic entry of foreign molecules the vesicles are approx. 100 nm in 
diameter.  Caveolae are small (approx. 50 nm in diameter).  Macropinocytosis which is a 
highly conserved endocytic process by which extracellular fluid and its contents are 
internalized into cells through large, heterogeneous vesicles approximately 0.5–5 µm in 
diameter known as macropinosomes.217 
The particle size for the DOX:ZrP materials is approximately 175 + 5 nm 
according to the DLS and TEM analysis. Based solely on size the macropinocytosis 
endocytotic pathway best fits the need to internalize the DOX:ZrP material. The 
confocal data is in agreement since the caveolae and clathrin shutdown pathways don’t 
affect the DOX:ZrP uptake. However the macropinocytosis shut down pathway 
significantly diminishing the nanoparticle uptake just as hypothesized. 
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Figure V-9: The various endocytotic pathways that maybe applicable for the uptake 
of drug loaded nanoparticles. (Reference 216)  
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Conclusions 
The in vitro studies suggest that application of ZrP nanoparticle mediated drug 
transport as exemplified by DOX:ZrP and cisPt:ZrP, is highly promising for cancer 
chemotherapy. This chapter discussed the synthesis and characterization of ZrP 
nanoparticles, and loaded DOX and CisPt in the nanoplatelets. The ZrP nanoparticles are 
not toxic to normal as well as malignant human cells. The ZrP particles can intercalate 
high loads of drugs and sustain their release. In the case of CisPt:ZrP samples the in vitro 
release of the Pt(II) complex is observable upon the introduction of a pH stimulus. We 
also demonstrate that the uptake mechanism of DOX-ZrP in HeLa cells was mediated by 
the macropinocytosis-mediated endocytic pathway.  
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary  
Drug delivery vehicles represent an important field of research that have 
tremendous potential to improve upon the therapeutic formulations of several current 
drugs. The opportunities for advancements in the field are numerous and still being 
discovered. The work of this dissertation aims to present significant improvements in 
four specific areas of inorganic layered material drug delivery technology: 
1. The surface modification of zirconium phosphate nanoplatelets for custom 
designed surfaces that can be functionalized for a variety of applications, 
including but not limited to drug delivery  
2. Establishing a novel technique to discover drug:ZrP nanohybrid homogeneity 
using secondary ion mass spectrometry (SIMS).   
3. The delivery of anticancer therapeutics using robust inorganic layered 
framework, ZrP to establish a direct correlation of anticancer drug-ZrP 
nanohybrid  homogeneity with in vitro drug release efficiency     
4. The uptake mechanism of DOX:ZrP nanohybrids in HeLa cells was mediated by 
the macropinocytosis-mediated endocytic pathway to provide insights in 
identifying their organelle and molecular targets.  
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 The results presented here show significant advancements in the area of 
inorganic layered frameworks for drug delivery. While polymeric drug delivery 
agents have been well investigated, the realm of inorganic material drug delivery is 
still relatively new.  Adding to the drug delivery vehicle toolkit available to 
researchers and clinicians, these techniques can aid in overcoming the difficulties in 
anticancer therapeutics as well as having a broader impact on the field of drug 
delivery as a whole. The following sections will reiterate the important conclusions 
presented by this work and introduce a novel new technique to monitor non 
fluorescent CisPt:ZrP nanohybrids within cellular milieu without fluorescent tags.  
 
Future Directions    
 In the past decade significant progress has been made in the imaging of 
chemical species within intact cells using secondary ion mass spectrometry, 
including the simultaneous mapping of subcellular elemental and molecular species 
along with intrinsic membrane-specific cellular markers.218 The method presented in 
this chapter discusses the future of specimen preparation and chemical imaging of 
cell interiors providing the foundation for obtaining 3D molecular maps of small 
molecule distribution within unstained HeLa cells.  Knowledge of the spatial 
distributions of elements within cells is potentially important for understanding the 
delivery and release of drug:ZrP nanohybrids. Since fluorescence imaging is 
restricted to natively fluorescent materials or requires fluorescent tagging, using 
SIMS based imaging techniques provides unique opportunities for achieving 
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simultaneous detection of multiple, unlabeled cellular components. This chapter 
covers some of the challenges in developing sample preparation/preservation 
protocols that maintain the chemical integrity of the cells. This chapter presents an 
approach to accomplish the aim of single cell mass spectrometric imaging for 
specific drug delivery target detection.  
 The instrumentation used to carry out these experiments is housed at the 
National Institute of Standards and Technology (NIST; Gaithersburg, Maryland). 
The instrumentation is described in detail elsewhere.218 Briefly, the secondary ion 
mass spectrometer uses a Ga+ focused ion beam (FIB) to mill flash frozen HeLa 
cells. The exposed cellular interiors are interrogated by SIMS. The information 
obtained from each targeted pixel can be used to extract characteristic elemental and 
molecular ion information for the desired polarity en route to a microchannel plate 
detector. Element specific maps are generated for individual chemical species. A 
computational algorithm identifies distinct cellular and molecular fragment 
localizations.  Overlays of these localizations produces detailed molecular maps of 
molecular chemistries within and around single cells.218 
 
Sample Preparation Procedure    
Strategy for nanoscale compositional mapping of biological molecules in 
mammalian cells is illustrated in Figure VI-1. HeLa cells are (1) grown on silicon 
substrates immersed in media, (2) plunge-frozen in liquid ethane, and (3) freeze-
dried and gently rinsed with mass spectrometry-grade water. The step-wise 
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procedure that was developed in conjunction with National Institute of Health (NIH) 
and NIST is described below.   
1.  HeLa cells were grown on sterilized silicon wafers. Each silicon substrates is 
sterilized via the following rinses:  70 % ethanol for 5 minutes, doubly 
distilled water for 10 minutes, 100 % ethanol for 5 minutes, and HPLC-grade 
water for 10 minutes.  
2. All preps were performed in a process free of contamination from 
poly(dimethylsiloxane) (PDMS), a common surface contaminant towards 
which the SIMS analysis are sensitive. After allowing the silicon wafers to air 
dry  (in a tissue culture hood), silicon pieces were cut with a diamond scribe 
from 5 mm x 5mm pre-diced squares to approximately 2 mm x 2 mm pieces 
and placed in cell wells.   
3. HeLa cells were grown in RPMI media, a general purpose media with a 
broad range of applications for mammalian cells containing 10 % fetal bovine 
serum (FBS) overnight.  HeLa cells were split and seeded into the wells and 
allowed to culture overnight.  
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4. Each of the wafers had HeLa cells grow onto them at a density of 106 cells/ml 
with roughly ~20uL of the cell solution being used to drop cast onto the 
wafer for 30 min to allow attachment followed by addition of more cell 
populated media. Different growth conditions were tested Figure VI-2.    
5. Once the cells were confluent (2 days post growth) the CisPt:ZrP material 
was introduced in each cell well at the specified concentration. (Table VI-1)   
Six hours post incubation with the drug/sample the cells were washed with 
phosphate buffer with 10% bovine serum albumin (BSA). This step was done 
to get rid of various components of cell culture media, so that the background 
spectra from SIMS would be clean.  
6. Post washing the cells were lightly rinsed with Millipore water and the excess 
liquid wicked away with filer paper before they were quickly plunge frozen 
in liquid ethane 
7. Post plunge freezing they were stored in N2 dewars until they were freeze 
dried in a Balzers instrument at 2 X 105 Barr for 2 hours at -100°C after 
which the samples were allowed to revert to STP by slow leaking of the 
vacuum over time. This was done over roughly 5 hours. The instrumentation 
used in this process was a Balzers freeze-fracture electron microscope 
(Figure VI-3). 
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8. Resulting freeze-dried cells on silicon pieces were gently rinsed in a small 
volume of HPLC-grade water for 5 seconds, and the water wicked away with 
filter paper quickly.  This final step removes the majority of salt 
contamination on the silicon chip while maintaining the membranous 
structure of the cell. 
9. To wash the wafer allow a drop of clean water to touch the surface (not even 
fall on the surface, just contact it) for a few seconds, then wick away to any 
chosen side (don’t touch the top face) by holding the Si on its side with a pair 
of tweezers and letting it rest on a whatman filter paper. 
10. At this stage the samples are ready for storage and transport since the cells in 
question are unanimated and vacuum ready.  
 The preliminary results from the first round of experiments were presented 
in Figure VI-4. The images in Figure VI-4 depict time-of-flight (TOF)-SIMS 
compositional maps of several individual unstained HeLa incubated with CisPt:ZrP 
following plunge-freezing in liquid ethane and lyophilization to remove vitrified water. 
Both the total ion image (i.e., sum of all elemental and molecular ion intensities obtained 
in each pixel) and an overlay of the phosphatidylcholine headgroup (m/z 184) from the 
cell surface and extracellular sodium (m/z 23) are shown in Figure VI-4 a,&b. Parts c 
and d of Figure VI-4 display the individual ion-specific maps of the drug substrate, ZrP 
localized with part of the lipid head group (CN-) and the drug CisPt, respectively. 
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It is interesting to note that the ZrP and CisPt are also localized within the HeLa cells. 
The colocalization of the lipid signal to the periphery of each cell is indicative of 
chemically intact membranes. Additionally the observance of sodium on the cell 
substrate more so than the cell surface serves as verification for the sample preparation 
process. If the cells rupture during cell preparation, the lipid signal is homogeneous due 
to the formation of lipid raft like structures across the imaging area and not confined to 
the cell shapes (Figure VI-4f).  
 
Final Remarks 
This study lays the basic foundation for sample preparation needs in looking at 
drug metabolites within single cellular environments. While this study does open up 
possibilities for several non-fluorescent drugs and metabolites the complexity involved 
during sample preparation still requires more calibration for consistency. Because of the 
complexity of the ionic species desorbed from within and around single cells, as well as 
the difficulty in maintaining the chemical integrity of the cellular targets, care must be 
taken to have the proper sample preparation, sample analysis conditions that represent 
the optimum trade-off of spatial resolution and mass resolution.218 This is an important 
direction for the future of discoveries in inorganic drug loaded nanomaterials.  It will 
enable better analytical understanding of both the materials that play host for drug 
delivery as well as elevate the understanding of future delivery systems within cellular 
milieu. The next step in this work should be the introduction of a mouse model to test 
the efficacy of the inorganic layered materials in drug delivery applications. While in-
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vitro work does provide a very useful snapshot of expected immunoresponse, in vivo 
work will take this novel research to the next level.   
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